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The recycling of hemoglobin from damaged or senescent red blood cells (RBCs) 
contributes almost 90% of daily body iron requirements in humans for bone marrow 
erythropoiesis. Previously, our cell biological studies have shown that HRG1, a four 
transmembrane protein first discovered in C. elegans, facilitates the transport of heme 
within reticuloendothelial system (RES) macrophages during the turnover of RBCs, a 
process termed erythrophagocytosis. HRG1 transports heme from the 
phagolysosomes into the cytosol where heme is degraded to liberate iron for 
erythropoiesis. Here we show that mice deficient for HRG1 are defective in heme-
iron recycling by RES macrophages, resulting in over ten-fold excess heme 
accumulation as visible dark pigments within lysosomal compartments that are 10-
100 times larger than normal. The sequestered heme is tolerated by macrophages 
through polymerization into crystallized hemozoin, a phenomenon typically observed 
in blood-feeding parasites as a detoxification method to protect against heme toxicity. 
HRG1-/- mice display ineffective bone marrow erythropoiesis which results in a 
  
reduction in hematocrit and extramedullary erythropoiesis in the spleen. Under iron-
deficient conditions HRG1-/- mice are unable to utilize hemozoin as an iron source to 
sustain erythropoiesis, causing severe anemia and lethality.  Our studies establish that 
polymerizing cytotoxic heme into hemozoin is a previously-unanticipated heme 
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Chapter 1 : Introduction 
Heme is a tetrapyrrole that functions as a signaling molecule or cofactor to 
support numerous biological processes. As an iron-containing porphyrin, heme 
metabolism is invariably related to the metabolism of the inorganic micronutrient, 
iron. However, in comparison to iron, the mechanisms of inter- and intra-cellular 
heme transport are less clearly defined. Delineation of heme transport pathways has 
remained challenging due to the high binding affinity of heme to cellular proteins 
which maintains the low concentration of cellular labile heme at ~0.4 µM1. The 
utilization of genetics and whole animal nutritional studies in an animal model of 
heme transport deficiency represent our current efforts to define the necessity of heme 
transport in maintaining iron and heme homeostasis.  
Heme Biosynthesis 
In eukaryotic cells, heme is typically synthesized via a widely-conserved 
eight-step pathway which requires coordinated substrate transport between 
mitochondria and the cytosol2. The first step occurs in the mitochondrial matrix and is 
catalyzed by δ-aminolevulinic acid synthase (ALAS), resulting in the synthesis of δ-
aminolevulinic acid (ALA) from glycine and succinyl-coenzyme A. Subsequently, 
ALA is transported out of mitochondria and into the cytosol where four enzymatic 
reactions follow: 1) ALA is converted to porphobilinogen (PBG) by ALA 
dehydratase (ALAD); 2) PBG to an unstable polymer hydroxymethylbilane by 
porphobilinogen deaminase (PBGD); 3) hydroxymethylbilane to uroporphyrinogen 





coproporphyrinogen III (CPgen III) by uroporphyrinogen decarboxylase (UROD). 
CPgen III is then transported back into mitochondria where coproporphyrinogen 
oxidase (CPOX), a mitochondrial intermembrane space enzyme, catalyzes the 
formation of protoporphyrinogen IX (PPgen IX). PPgen IX is then converted to 
protoporphyrin IX (PPIX) by the inner mitochondrial membrane enzyme 
protoporphyrinogen oxidase (PPOX). The final step requires ferrochelatase (FECH) 
which facilitates the insertion of ferrous iron (Fe2+) into PPIX to form heme. 
Therefore, heme is a tetrapyrrole made up of an iron-protoporphyrin complex. The 
electrical charge of the molecule is dependent on the ionic state of the central iron 
atom: heme, or ferroprotoporphyrin, is electrically neutral as the iron atom is in the 
ferrous (Fe2+) state while hemin, or ferriprotoporphyrin, is positively charged as the 
iron atom is in the ferric (Fe3+) state. Heme contains four methyl groups, two vinyl 
groups, and two propionic acid groups as side chains and is hydrophobic in nature3. 
Iron metabolism in mammals 
Iron acquisition 
Iron is a trace element essential to eukaryotic life. In mammals, absorption of 
inorganic iron begins with the reduction of ferric (Fe3+) to ferrous (Fe2+) iron, often 
catalyzed by the membrane-associated ferrireductase duodenal cytochrome b (Dcytb)4 
(Fig. 1.1). Divalent metal transporter 1 (DMT1/SLC11A2), solute carrier family 11 
member 2, or natural resistance-associated macrophage protein 2 (NRAMP2) 
catalyzes the transport of Fe2+ across the apical membrane in the duodenal epithelia5 
(Fig. 1.1). Export of Fe2+ out of the intestinal epithelia and into circulation is 





Ferroportin-associated export of Fe2+ is coupled to the oxidation of Fe2+ into Fe3+ by 
ferroxidases, the serum ceruloplasmin (Cp) or membrane-bound hephaestin (Heph) 
(Fig. 1.1). Hephaestin is expressed on the basolateral membrane of duodenal 
enterocytes and physically interacts with ferroportin for iron export6. Fe3+ is 
subsequently bound by apo-transferrin (apo-Tf), which transports the redox inert iron 
to various tissues. Each Tf molecule contains two Fe3+ binding sites and under 
physiological iron conditions, plasma Tf is only partially saturated with iron (30-
40%)7. The reservoir of abundant unsaturated apo-Tf acts as a buffer, which allows 
efficient binding when plasma iron levels increase. This buffering capacity prevents 
the buildup of non-transferrin-bound iron (NTBI), which is a major contributor to 
tissue iron loading in iron overload disorders as NTBI taken up by tissue parenchymal 
cells8. During iron overload, NTBI builds up when the levels of plasma iron exceeds 
the buffering capacity of transferrin at about 60% saturation. NTBI overload is 
directed mainly to the liver and NTBI import into hepatocytes occurs through 
ZIP14/SLC39A149. In the absence of ZIP14, NTBI loading in the liver and pancreas 







Figure 1.1 Iron metabolism in mammals 
Ferric iron (Fe3+) is converted by Dcytb into ferrous iron (Fe2+) and transported into 
intestinal epithelial cells via DMT1 at the apical surface. Ferroportin (Fpn) exports 
Fe2+ through the basolateral surface of the epithelia where Fe2+ is converted into Fe3+ 
by ceruloplasmin (Cp) or hephaestin (Heph). Transferrin (Tfn) binds Fe3+ and 
transports iron through the circulation to different sites such as the bone marrow. 
Erythropoiesis in the bone marrow is stimulated by erythropoietin (EPO) secreted by 
the kidney. Erythrocytes remain in circulation and are phagocytosed in the spleen and 
liver upon senescence. Iron storage in tissues such as the liver is mediated by ferritin 
(Ftn). The liver produces hepcidin (Hamp), which negatively regulates iron 
absorption through Fpn. Hepcidin is in turn negatively regulated by erythroferrone 





Heme as a dietary iron source 
Another major dietary source of iron is heme, which has been shown to be 
more readily absorbed than inorganic iron in the human intestine11,12. In the intestine, 
heme is taken up by enterocytes as an intact metalloporphyrin13,14, although the 
molecules responsible for intestinal heme uptake remain unknown. Intestinal heme 
uptake was initially demonstrated in swine and canine animal models using 
[59Fe]heme. In intestinal brush border extracts isolated from adult pig duodenum, 
heme absorption and binding to a “heme receptor” was observed through 
spectrophotometric measurements15. A high-affinity heme-binding protein extracted 
from microvilli membranes of enterocytes was proposed to facilitate heme 
internalization into vesicles. In a different study, Mongrel dogs were fed with a diet 
containing [59Fe]hemoglobin to evaluate dietary heme absorption16. The dogs were 
made iron-deficient by phlebotomy and fed with hemoglobin. In iron-deficient dogs, 
higher plasma [59Fe]heme levels and greater [59Fe]hemoglobin absorption was 
observed. Based on these studies, two long-standing hypotheses of intestinal heme 
uptake were proposed. The first hypothesis, receptor-mediated endocytosis, arose 
from early studies on the “heme receptor protein” (described above)15 and the second, 
transporter-mediated uptake17 was conceived after heme transporters such as FLVCR1 
(Feline leukemia virus subgroup C receptor-related protein 1) and HCP1 (heme 
carrier protein 1) were discovered. FLVCR1, a cell surface heme exporter involved in 
erythroid cell maturation, prevents cell toxicity by exporting excess intracellular 





independently characterized as a folate transporter19. Therefore, the bona fide 
intestinal heme transporter remains elusive. 
Iron storage and distribution 
In humans, there exists a total of ∼3–5 g of iron5 and 70% of total body iron 
(>2 g) exists in red blood cells (RBCs). Within RBCs, majority of the total iron is 
stored as heme in hemoglobin20. A portion of iron is also found as heme present in 
myoglobin of muscles (∼300 mg). Macrophages residing within the spleen, liver, and 
bone marrow, collectively termed reticuloendothelial macrophages store a transient 
fraction of iron (∼600 mg), while excess iron (∼1000 mg) is stored within cellular 
ferritin in liver parenchymal cells. A minimal amount of intracellular iron is also 
bound to proteins and enzymes (∼8 mg)6.  
Tissue iron not utilized in biological processes is stored within a cytosolic 
heteropolymer protein made of 24 subunits of heavy (FTH1) and light (FTL) ferritin 
chains, together known as the ferritin nanocage. Although both FTH1 and FTL are 
ubiquitous, the ratios of FTH1 and FTL expression vary between tissues and 
physiological conditions. FTL is predominantly found in iron storage tissues, while 
FTH1 is preferentially expressed in cells that acquire and export iron rapidly. Each 
ferritin nanocage can store up to 4500 iron atoms. FTH1 contains the ferroxidase 
activity required for the conversion of Fe2+ to Fe3+ for iron mineralization into the 
polymer while the enzymatically inactive FTL facilitates the transfer of electrons 
across the protein shell of the polymer21. In plasma, a glycosylated FTL subunit 
circulates and exhibits a low level of saturation with iron, although its origin and 





shown to increase in response to systemic iron overload or infection, and are therefore 
commonly used as biomarkers of such physiological conditions22.  
The mechanism of iron delivery to ferritin is aided by the cytosolic iron 
chaperone of Poly r(C)-binding protein (PCBP)23. PCBP1 and its paralog PCBP2 
were shown to interact at high affinities with ferritin in HEK293 cells. In yeast, the 
concurrent expressions of PCBP1, PCBP2, and human ferritins activate an iron-
deficiency response by increasing iron deposition into ferritin. However, only the 
knockdown of PCBP1 but not PCBP2 resulted in an impaired iron utilization 
phenotype during RBC maturation. Mice lacking PCBP1 develop microcytic anemia 
as a result of ineffective RBC maturation24. 
Cellular iron stores can be mobilized by ferritin degradation. Under iron-
deficient conditions, NCOA4 (Nuclear Receptor Coactivator 4) interacts with FTH1, 
which targets the ferritin complex for degradation in autolysosomes. This stimulates 
release of ferritin iron stores in a process known as ferritinophagy. In iron-replete 
conditions, cellular ferritinophagy is suppressed due to increased NCOA4 turnover25. 
NCOA4-deficient mice do not experience ferritinophagy, resulting in cellular ferritin 
accumulation and iron-deficiency anemia. The increase in cellular iron storage by 
ferritin accumulation causes an imbalance in systemic iron distribution and reduces 
iron availability for developing erythroblasts26.  
Systemic iron regulation 
As ferroportin is the only known mammalian exporter of inorganic iron and 
ferroportin inactivation enhances intracellular iron retention, a critical regulation of 





hepcidin negatively regulates ferroportin by binding to ferroportin on the plasma 
membrane of cells including enterocytes, macrophages, and hepatocytes. This 
interaction induces phosphorylation and internalization of ferroportin, resulting in its 
lysosomal degradation27,28. Hepcidin has also been implicated in the proteasomal 
degradation of DMT129.  
Hepcidin (Hamp) is produced as an 84 amino acid precursor propeptide30 
(Fig. 1.1). Post translationally, the prohormone convertase furin cleaves hepcidin into 
a biologically active 25 amino acid mature peptide, which is subsequently secreted 
into plasma31.  Regulation of hepcidin expression occurs at the transcriptional level 
via the CCAAT enhancer-binding protein α (C/EBPα). C/EBPα binds to a CCAAT 
motif within the HAMP promoter to maintain its basal transcriptional activity32. Basal 
hepcidin expression is also shown to be maintained by Alk3, a type I bone 
morphogenetic protein (BMP) receptor33. In iron-deficiency, hepcidin repression 
occurs to trigger iron absorption and release of iron stores for increased 
erythropoiesis. Erythropoiesis is dependent on the kidney-produced cytokine 
erythropoietin (EPO) and recently, an EPO-responsive erythroid regulator of 
hepcidin, named erythroferrone (ERFE, also known as FAM132B and myonectin) 
was identified34 (Fig. 1.1). EPO induces erythroblastic ERFE secretion by signaling 
through the JAK2/STAT5 pathway34. ERFE-deficient mice are unable to suppress 
hepcidin during hemolysis or EPO stimulation34. Hepcidin expression can be induced 
by a variety of stimulants including hepatic iron loading or inflammation, leading to 





Hepcidin transcription is induced upon hepatic iron loading via the BMP 
signaling pathway35. Hepatic iron induces expression of BMP6 and mRNA levels of 
BMP6 are correlated to hepatic iron loading in mice36. BMP6 (and other BMP 
ligands) binding to BMP receptors induces phosphorylation of SMAD1, SMAD5, and 
SMAD8 proteins33. The phosphorylated SMAD1/5/8 complex together with SMAD4 
binds to the BMP responsive elements on the hepcidin promoter and stimulates 
hepcidin transcription37. Mice with a liver-specific disruption of BMP receptors Alk2, 
Alk333, or SMAD438 display defects in iron-induced hepcidin expression39. Mice 
lacking hepatic BMP6 are unable to induce hepcidin and therefore suffer from iron 
overload40,41. Conversely, treatment of recombinant BMP6 in mice leads to increased 
production of hepcidin and hypoferremia41. 
Cellular iron regulation 
Cellular iron metabolism, unlike systemic iron metabolism, is highly regulated 
at the post-transcriptional level by iron regulatory proteins (IRPs) in the cytoplasm. 
IRP1 and IRP2 bind to iron-responsive elements (IREs) on mRNAs and the 
interaction often determines the fates of iron-related mRNAs. Removal of either IRP1 
or IRP2 is not lethal, but the ablation of both IRPs results in embryonic lethality at the 
early blastocyst stage42. The absence of both IRPs in the intestine has been associated 
with defects in growth and ineffective intestinal absorption, indicating the importance 
of IRPs in the intestine and duodenum43 while hepatocyte-specific removal of IRPs 
leads to liver damage and premature death44. 
Under iron-replete conditions, IRP1 acquires an iron-sulfur cluster (4Fe-4S) 





iso-citrate. The aconitase form of IRP1 is unable to bind to IREs.  By contrast, the 
4Fe-4S cluster is absent in IRP1 during iron-deficiency which allows for subsequent 
IRE-binding by IRP145. Unlike IRP1, IRP2 is regulated by a different mechanism. In 
iron-replete conditions, IRP2 is ubiquitinated by FBXL5, an E3 ubiquitin ligase, and 
undergoes proteasomal degradation46. FBXL5 ablation in mice causes death early in 
embryogenesis, due to iron accumulation and iron-induced tissue damage47. The 
FBXL5-ablation-associated death could be prevented by an additional ablation of 
IRP2, consistent with the notion of FBXL5 being a repressor of IRP247.  
IREs are evolutionarily conserved structural motifs present in mRNAs within 
the untranslated regions (UTRs).  IRPs bound to IREs in the 5’ UTR obstructs 
translation while in the 3’UTR stabilizes the mRNA.  IREs are stem–loop structures 
which consist of 25–30 nucleotides48. A major regulation of cellular iron status occurs 
via the IRE-IRP-mediated post-transcriptional regulation of transferrin receptor 
(TfR1) mRNA which contains multiple IREs within its long 3′ UTR. Ferritin FTH1 
and FTL mRNAs contain a single IRE in the 5’ UTR and is also regulated by IRP 
interaction under various cellular iron conditions. 
In iron-deficient conditions, IRPs bind to IREs on the TfR1 mRNA with high 
affinities (Kd ≈ 10–12 M). On the TfR1 mRNA, IRP binding leads to enhanced 
stability of the mRNA. On the contrary, IRP-IRE interaction on ferritin mRNA leads 
to translational inhibition of the mRNA. TfR1 protein therefore accumulates, 
enhancing the cellular uptake of iron from circulating Tfn. Ferritin production 
decreases, preventing iron storage and accumulation, promoting iron utilization. In 





production and increased ferritin production. This minimizes cellular iron uptake by 
TfR1 and induces iron storage by cellular ferritin45. Certain mRNAs encoding iron 
metabolism proteins such as DMT1 and Fpn exists as both IRE and non-IRE 
isoforms. The expression of the IRE or non-IRE isoform is dependent on tissue and 
cellular specificity. For example, in duodenal enterocytes and erythroid precursor 
cells, Fpn exists predominantly as the non-IRE isoform49. Expression of the non-IRE 
isoform reduces the occurrence of IRP-IRE interactions and allows for efficient iron 
transport in these cell types during iron-deficiency.  
Iron-deficiency and inflammation 
Iron-deficiency has long been known as a consequence of the inflammatory 
stress response and used by the body as a strategy to confer resistance to infection. 
This association is best described by anemia of inflammation, also known as the 
anemia of chronic disease (ACD). ACD is characterized as hypoferremia, low plasma 
iron-binding capacity and normal-to-elevated ferritin levels. The reduction in iron 
availability can be largely attributed to the hepcidin-ferroportin iron regulation axis 
through upregulation of hepcidin. The response can be reproduced in mice by the 
overexpression of hepcidin50. Hepcidin is produced in the liver in response to the 
inflammatory cytokine interleukin-6 (IL-6)51 and can also be produced by immune 
cells such as macrophages upon stimulation through a toll-like receptor-4 (TLR-4) 
dependent pathway52,53. It has also been shown that other cytokines such as IL-1β can 
induce hepcidin production54. While hepcidin is a major regulator of iron during 
inflammation, it is noteworthy to mention that other pathways also contribute to the 





mediated effects elicited by tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-
γ)55. 
Both TNF-α and IFN-γ are pro-inflammatory cytokines that function to 
modulate iron status independent of the induction of hepcidin. Increased TNF-α 
levels promotes hypoferremia56 and are associated with systemic iron-deficiency in 
humans57. TNF-α treatment in mice leads to a decrease in intestinal iron absorption58, 
speculated to hence cause iron-deficiency. IFN-γ modulates the innate immune 
response through the stimulation of nitric oxide (NO) synthesis, catalyzed by the iron-
regulated inducible NO synthase (iNOS). Iron inhibits IFN-γ, resulting in an inverse 
relationship between cellular iron status and iNOS expression59. In vivo studies show 
that a high-iron diet suppresses IFN-γ production60, suggesting that iron loading 
represses the systemic inflammatory response. 
Erythroid lineage development 
Steady state erythropoiesis 
Definitive erythropoiesis in adult mammals occurs predominantly in the bone 
marrow and arises from hematopoietic stem cells (HSCs) derived from pluripotent 
stem cells within the tissue. HSCs then give rise to the first erythroid lineage-
committed progenitor cells known as the burst-forming unit-erythroid (BFU-E). Slow 
proliferating BFU-Es then divide and differentiate into colony-forming unit-erythroid 
(CFU-E). Subsequently, CFU-Es divide rapidly over the span of 2-3 days and 
undergo major cellular changes to become erythroblasts61. The proliferation and 
differentiation of CFU-Es to erythroblasts is controlled by the cytokine, 





conditions, provides the extracellular stimulus for CFU-E differentiation. EPO binds 
to the EPO receptor on the surface of erythroblast progenitors, resulting in a signaling 
cascade that induces differentiation. EPO appears to function during CFU-E 
differentiation through multiple pathways, including the signal transducer and 
activator of transcription 5 (Stat5) and phosphoinositide-3 kinase/Akt (PI3K/Akt) 
pathways62,63. Defects in either of the two pathways result in erythroid progenitor cell 
death and reduction in erythropoietic output. Post-CFU-E differentiation, erythroid 
maturation continues with erythroblast development within the bone marrow niche. 
The earliest erythroblast stage is called the proerythroblast, which undergoes 
proliferation and differentiation to give rise to four consecutive stages of 
erythroblasts. The order of maturation occurs from proerythroblast to basophilic, 
polychromatic and orthochromatic erythroblasts. Orthochromatic erythroblasts then 
undergo nuclear expulsion to become reticulocytes, which are the terminal stage of 
differentiation before erythrocytes are released into circulation. Each distinct stage of 
erythroblast maturation is distinguished by cell size and membrane protein 
composition. The differentiation of erythroblasts is also accompanied by enhanced 
chromatin condensation and progressive hemoglobinization. Two common cell 
surface membrane proteins used to distinguish erythroblastic stages are transferrin 
receptor 1/CD71 and CD44, an adhesion molecule. Both proteins are expressed at 
high levels in developing erythroblasts but not expressed on mature erythrocytes. As 
different stages of maturing erythroblasts express different levels of CD71 and CD44, 
these markers are used in conjunction with Ter-119, an erythroid-specific cell surface 





erythroblasts coincides with the increase in hemoglobin production, and expression of 
the EPO receptor, TfR1, ALAS2 and globin at varying time points (Fig. 1.2). Using 
flow cytometry, the combination of Ter-119, CD71 or CD44 and cellular size allows 







Figure 1.2 Erythroblast maturation 
Hematopoietic stem cells (HSCs) give rise to burst-forming unit-erythroid (BFU-E) 
which matures into colony-forming unit-erythroid (CFU-E). The erythroid lineage 
continues by maturation into proerythroblast, then basophilic, polychromatic, 
orthochromatic, reticulocyte and terminal differentiation into erythrocytes. The 
maturation occurs with hemoglobin formation and expression of Ter119, EPO-
receptor, transferrin receptor 1, ALAS2 and globins production. 
Extramedullary erythropoiesis 
Steady state erythropoiesis, mostly occurring in the bone marrow, produces 
new erythrocytes at a constant rate. In contrast, stress or extramedullary 
erythropoiesis, observed in mice spleens and livers, is capable of generating large 





(EBIs) also facilitate stress erythropoiesis in the spleens of mice, although the process 
utilizes stress erythroid progenitor (SEPs) cells that are distinct from the steady state 
erythroid progenitors in the bone marrow65,66. Furthermore, stress-induced EBIs in the 
spleen contain nurse macrophages derived from recruited circulating monocytes. 
These monocytes, together with SEPs, develop into stress-induced EBIs to support 
extramedullary erythropoiesis66. 
Stress erythropoiesis is induced during anemia as anemia induces tissue 
hypoxia, which in turn causes the transcriptional activation of EPO in the kidney. The 
3’-flanking region of the EPO gene contains a hypoxia-inducible enhancer, which is 
the target of the transcription factor hypoxia-inducible factor 1 (HIF-1)67. While EPO 
plays a significant role in the expansion and terminal differentiation of bone marrow 
erythroid progenitors during stress erythropoiesis68, the expansion of erythroid 
progenitors in the spleen also relies on other key signals including BMP4, which 
induces the expansion of BFU-E in the spleen to promote recovery from acute 
anemia65. It is noteworthy that hypoxia also regulates the induction of BMP4 
expression in the spleen69 and is required for the maximal stress response of SEPs to 
BMP470. The BMP4 gene contains two hypoxia responsive elements that regulate 
gene expression through the transcription factor hypoxia-inducible factor-2α (HIF-2 
α)65. 
Iron metabolism during erythropoiesis 
Erythroid differentiation is accompanied by high levels of hemoglobin 
synthesis. This relies on an efficient pathway to uptake extracellular iron to provide 





transferrin receptor 1 (TfR1), which binds circulating iron-bound transferrin at high 
affinities. One transferrin molecule binds two ferric iron atoms with an association 
coefficient of 10-20 M at physiological pH and is referred to as holo-Tf71. When 
bound, the holo-Tf-TfR1 complex undergoes receptor-mediated endocytosis, 
resulting in internalization and subsequent release of ferric iron upon endosomal 
acidification. Six-transmembrane epithelial antigen of prostate 3 reductase 
(STEAP3)72 catalyzes the reduction of Fe3+ into Fe2+ which is transported out of the 
endosome by divalent metal transporter 1 (DMT1/NRAMP2/SLC11A2)73. After iron-
release, the apo-Tf-TfR1 complex is transported back to the cell surface, and apo-Tf 
dissociates from TfR1 and re-enters the circulation. The Tf-TfR1-mediated iron 
transport cycle ensures that developing erythroblasts optimize iron uptake from the 
circulation to sustain maximal hemoglobin production. 
Iron transport into mitochondria for heme synthesis is mediated by SLC25A37 
(mitoferrin1/MFRN1), a protein in the family of mitochondrial solute carrier proteins. 
MFRN1 is expressed in the inner mitochondrial membrane and transports iron across 
mitochondrial membranes74. Zebrafish with MFRN1 defects have significant 
hypochromic anemia and display erythroid maturation arrest due to insufficient 
mitochondrial iron uptake in erythroblasts. In yeast, the deletion of two MFRN 
homologs, Mrs3 and Mrs4 impairs incorporation of iron into PPIX and formation of 
Fe-S cluster assembly leading to poor growth under low iron conditions. MFRN1 
deletion in mice causes embryonic lethality and mouse erythroblasts obtained from 
MFRN1-deficient embryonic stem cells are unable to incorporate iron into heme 





hematopoietic tissues are unable to support erythroblast maturation and are severely 
anemic75. 
Heme synthesis in erythroid cells 
Erythroid heme synthesis contains unique regulatory mechanisms to ensure 
sufficient production of heme for hemoglobinization of developing erythroblasts. 
Heme synthesis precedes globin synthesis during erythroblastic differentiation due to 
the requirement of heme as a signaling factor in activating protein translation 
initiation. In the presence of sufficient cellular heme, heme binds and inactivates the 
heme-regulated eukaryotic initiation factor2α kinase (HRI), allowing protein 
synthesis to occur76. While the heme biosynthetic pathway in erythroid cells is largely 
similar as that in other eukaryotic cells, erythroid cells utilize an erythroid-specific 
isoform of ALAS called ALAS2 to catalyze the rate-limiting step of ALA synthesis77. 
Activation of ALAS2 is controlled by the erythropoietic regulator and transcription 
factor GATA1. The gene encoding ALAS2 contains two GATA1 binding elements, 
one in the first and in the eighth intron78,79. Removal of the GATA1 binding elements 
prevents ALAS2 expression and inhibits downstream heme biosynthesis, but can be 
overcome by supplementing cells with ALA, the product of ALAS2. ALAS2 is also 
regulated post-transcriptionally, via IREs in the 5’ UTR80. In iron-deficiency, ALAS2 
translation is inhibited by IRP-IRE binding while the converse occurs when iron 
levels are sufficient. The tight regulation of ALAS2 expression in erythroid cells is 
concomitant with cellular iron and heme levels. Due to the erythroid specificity of 





and X-linked protoporphyria76. These disorders result in anemia as erythroid cells are 
poorly hemoglobinized.  
The last step of heme biosynthesis catalyzed by FECH is also uniquely 
regulated in erythroid cells. For example, in the promoter region of the gene encoding 
FECH, both housekeeping and distinct erythroid elements exist81. Like ALAS2, 
FECH transcription is also regulated by GATA1 and FECH is highly induced during 
terminal erythroid differentiation82. It has also been reported that alternate splicing in 
the 3’ noncoding region of FECH mRNA occurs specifically in erythroid cells83. A 
deficiency in FECH leads to erythropoietic protoporphyria (EPP)84, where PPIX 
accumulates in erythrocytes, skin and liver of patients. PPIX accumulation manifests 
clinically as photocutaneous sensitivity and possibly liver disease76. 
In addition to the regulation of heme synthesis, globin synthesis in erythroid 
cells is also an important factor during hemoglobinization. Globin synthesis is 
regulated by heme via the BACH1 (BTB and CNC homology 1) transcription factor85. 
The coupling of heme synthesis and globin production ensures that sufficient globin 
is produced to meet the heme levels produced during erythroid differentiation. 
Macrophages in erythropoiesis 
Terminal erythropoiesis in the bone marrow has been observed to take place 
in a specialized microenvironment called the erythroblastic island. The erythroblastic 
island (EBI) was first observed in bone marrow sections using transmission electron 
microscopy in 195886. EBIs were characterized as a compound structure containing a 
central macrophage surrounded by developing erythroblasts86. Although the 





are still not well understood, it has been shown that nurse macrophages promote 
erythropoiesis by supplying iron to developing erythroblasts and stimulating the 
proliferation and survival of erythroblasts. In the absence of transferrin, in vitro 
cultures of macrophages were observed to secrete ferritin that were subsequently 
endocytosed by developing erythroblasts and used as a source of iron for heme 
production87. Furthermore, developing erythroblasts co-cultured and adhered to 
macrophages in vitro showed enhanced proliferation compared to erythroblasts 
cultured alone88. In addition to supporting the maturation and growth of developing 
erythroblasts, nurse macrophages also assist in the terminal maturation of a 
proerythroblast into a reticulocyte through phagocytosis of the expelled nuclei, 
known as a pyrenocyte89. Prior to phagocytosis, adhesion molecules including Emp90 
and β1 integrin91 expressed on the pyrenocyte facilitates retention of the pyrenocyte 
on the nurse macrophage surface. Emp-null mice fetuses die in utero and show a 
significant increase in the number of nucleated erythrocytes in the peripheral blood90. 
Nurse macrophages then degrade the phagocytosed nuclei using DNase II. DNase II-
deficient fetuses are incapable of supporting definitive erythropoiesis and contain 
fetal liver macrophages with ingested nuclei. They subsequently suffer from severe 
anemia leading to death in utero92. 
The macrophage-erythroblast interactions within EBIs also potentially involve 
the transport of heme. While the transfer of heme from erythroblasts to macrophages 
has not been shown, the cellular heme exporter FLVCR1a/b appears to be essential 
for erythroid maturation. FLVCR1a-deficient mice are unable to develop definitive 





maturation arrest93. FLVCR1b, the mitochondrial isoform, is required for 
erythropoiesis through mitochondrial heme efflux into the cytoplasm. In the absence 
of FLVCR1b, erythroid differentiation is also terminated94. It thus appears that 
erythroid precursors require heme export at both the mitochondrial and cellular level 
to regulate erythroid differentiation and to prevent excess intracellular heme 
accumulation and toxicity. 
Macrophage heme-iron recycling and transport 
The lifespan of erythrocytes in humans is about 120 days and each day, 20–25 
mg of iron flows through the hemoglobin cycle. Hence over 2.5 million erythrocytes 
are removed and replaced by new ones each day. Macrophages in the spleen, liver 
and bone marrow are central to the removal of damaged or senescent erythrocytes 
known as erythrophagocytosis. This process is important for the extraction of heme 
and eventually iron from erythrocytes95.  
As erythrocytes enter the spleen through blood circulation, they encounter 
macrophage receptors in the red pulp searching for the display of surface markers or 
antibodies that stimulate phagocytosis. Cellular changes by erythrocyte senescence 
must reach a specific threshold that causes recognition by splenic red pulp 
macrophages (RPMs) and induce erythrophagocytosis (EP) (Figs. 1.1, 1.2).  
A variation of cellular alterations on the erythrocyte membrane may lead to 
RPM erythrophagocytosis. One modification of aging occurs to Band 3, a chloride-
bicarbonate exchanger abundantly found on the erythrocyte membrane. As 
erythrocytes age, Band 3 membrane clustering occurs and is recognized as a marker 





binding of denatured hemoglobin to its cytoplasmic domain and may be induced by 
proteolytic cleavage or covalent modifications as erythrocyte age96. Band 3 clusters 
are recognized by opsonic natural antibodies and complement-triggering conventional 
antibody leading to complement-mediated phagocytosis by macrophages97. 
Phosphatidylserine (PS), normally found on the inner leaflet of the RBC membrane, 
is increasingly exposed as RBCs age and PS exposure correlates with RBC 
clearance98,99.  Erythrocyte senescence may also be accompanied by increased 
membrane rigidity and the loss of sialic acid and the CD47 antigen100. 
RPMs in the spleen are the main subtype of resident macrophages that 
phagocytose RBCs. The development of RPMs, characterized as 
F4/80hiTremL4+CD11blo cells, is dependent on the transcription factor SPIC. SPIC 
transcription is regulated by the transcriptional repressor BACH1, which is inhibited 
by heme binding on a dipeptide motif of cysteine and proline101. BACH1, a member 
of the basic leucine zipper family of transcription factors, forms heterodimers with 
small Maf proteins to control gene expression102. BACH–Maf heterodimers bind to 
Maf recognition elements (MARE) and suppresses gene expression of target genes 
such as Fpn102. When heme binds to BACH1, its DNA binding is altered thus 
inducing nuclear export of BACH1 and its subsequent ubiquitination and 
degradation103-105. In the splenic red pulp, heme induces degradation of BACH1 
protein in monocytes, leading to de-repression of SPIC and inducing the maturation 
of monocytes into RPMs. SPIC-deficient mice do not have RPMs but are normal for 





reduced capacity to recycle iron through erythrocyte recycling and accumulate iron in 
their spleens106.  
When RPMs engulf senescent or damaged RBCs, divalent metal transporter 
NRAMP1 (natural resistance-associated macrophage protein 1) and heme transporter 
HRG1/SLC48A1 (heme-responsive gene 1) are recruited to the phagosomal 
membrane107(Fig. 1.2). NRAMP1 transports iron out of the erythrophagosome and 
NRAMP1-deficient mice exhibit splenic macrophage iron retention when chronically 
treated with phenylhydrazine, a hemolytic agent108. HRG1 transports heme from the 
phagosomes into the cytosol of bone marrow-derived macrophages (BMDMs) during 
EP, where heme is subsequently degraded by heme oxygenase 1 (HMOX1) to liberate 
iron109 (Fig. 1.2). In addition, it has been suggested that cytosolic heme can be 
transported out of macrophages by FLVCR1110. FLVCR1-deficient macrophages have 
elevated ferritin levels following EP suggesting that FLVCR1 may function to export 
intact heme out of macrophages post-EP110 (Fig. 1.2). Heme-derived iron is then 
either stored by cytoplasmic ferritin or exported across the plasma membrane by 
ferroportin and transported in circulation by transferrin111 (Figs. 1.1, 1.2). The tightly 
regulated processes following EP ensure that 1) RBC heme-iron is efficiently 







Figure 1.3 Macrophage heme-iron recycling 
Reticuloendothelial system (RES) macrophages phagocytose senescent or damaged 
erythrocytes and recycle heme-iron through an intricate pathway. NRAMP1 
transports iron out of the phagolysosome where it can be bound and stored as ferritin 
iron or exported out of the cell by Fpn. HRG1 transports heme out of the 
phagolysosome and into the cytosol. Cytosolic heme can be exported by FLVCR1 or 
catabolized by HMOX1 to release iron. During hemolysis, heme and hemoglobin 
(Hb) released from erythrocytes are scavenged by hemopexin (Hpx) and haptoglobin 
(Hp), respectively. RES macrophages express the haptoglobin receptor CD163, which 







Secondary systems in mammalian heme handling 
In addition to HMOX1, which plays a major role in heme catabolism, 
mammals have also developed secondary systems designed to handle heme and 
prevent cellular toxicity from exposure to free heme. Haptoglobin (Hp) and 
hemopexin (Hpx) are two plasma heme scavenging proteins that protect cells from 
heme-mediated oxidative damage during hemolysis112. 
Hp has the highest binding affinity for hemoglobin (Hb) in plasma and also 
belongs to the family of acute phase proteins; Hp synthesis is induced by cytokines 
during inflammation113. Haptoglobin (Hp) is synthesized by the liver as a single 
chain, but subsequently cleaved into an N‐terminal light α‐chain and a C‐terminal 
heavy β‐chain114. The two chains associate through an intermolecular disulfide bond 
between two cysteines115. In plasma, Hp binds Hb at a stoichiometric ratio of 1:1 and 
the complex exists as ferric-Hb-Hp molecules116. Hp sequestration of Hb reduces Hb 
oxidation to release heme and Hp-Hb complexes are endocytosed by tissue resident 
macrophages in various tissues expressing CD163117. Endocytosis of Hp-Hb 
complexes facilitates the clearance of hemoglobin from the circulation during 
hemolysis. In addition to macrophages, hepatocytes also endocytose Hp-Hb 
complexes which subsequently dissociate into Hp and Hb and are individually 
degraded intracellularly118. 
Hemopexin (Hpx), a 60 kDa glycoprotein found in plasma, consists of a single 
polypeptide chain (439 aa) with 20% carbohydrate119. Hpx, which binds heme non-





binding protein120. Hpx is made up of two non-disulfide linked, structurally related 
domains that together bind a single heme molecule. The N-terminal domain can bind 
heme independently while the C-terminal domain facilitates the binding of Hpx to its 
receptor121. Hpx is mainly produced by liver hepatocytes but has also been observed 
to be synthesized by neurons of the peripheral nervous system and human retinal 
photoreceptor and ganglion cells122-124. The binding of Hpx to heme in circulation 
maintains heme in aqueous environments as a soluble monomer117. Hpx-heme 
complexes cause less oxidative damage than free heme and are protective during 
hemolysis, demonstrating the anti-oxidant properties of Hpx125. Hemopexin-deficient 
mice suffer from severe renal damage and are defective in recovery after acute 
hemolysis126. Hpx-heme complexes are predominantly endocytosed by liver 
parenchymal cells through the Hpx receptors where heme is released intracellularly 
from the complex for HMOX-mediated degradation and Hpx is recycled back into the 
circulation127. 
Heme catabolism and toxicity 
Mammals degrade heme into biliverdin, carbon monoxide (CO) and iron via 
the catalytic activity of heme oxygenases (HMOXs). HMOXs consist of two 
isozymes, the inducible form HMOX1 and constitutive form HMOX2. HMOX1 is 
known to be predominantly expressed in sites such as the liver and spleen128,129 while 
HMOX2 is predominantly expressed in the brain and testis130. HMOX1 and HMOX2 
are both anchored at their C-termini to the endoplasmic reticulum (ER) by a stretch of 
~19 hydrophobic amino acids which forms the transmembrane segment131. HMOX1 





conserved region; the C-terminal membrane anchors contain similarities but are less 
conserved (∼15%)132. The degradation of heme by HMOX requires the activity of 
NADPH-cytochrome P-450 reductase, which is also anchored similarly to the ER 
membrane133. Utilizing three moles of oxygen and seven electrons supplied by 
NADPH-cytochrome P-450 reductase, HMOX cleaves the alpha-methane bridge of 
the porphyrin ring of heme to liberate iron and CO with equimolar amounts of 
biliverdin134. Together with NADPH, the cytosolic enzyme biliverdin reductase 
subsequently converts biliverdin into bilirubin135. Intracellular bilirubin is excreted 
into plasma and transported to the liver by association with serum proteins such as 
albumin. In the liver, bilirubin undergoes glucuronidation by hepatic phase II UDP-
glucuronyltransferases which results in solubilization of bilirubin, preventing its 
intestinal reuptake. The conjugated bilirubin is then excreted through bile and 
feces136. 
Heme catabolism by HMOX1 is essential as observed by >90% embryonic 
lethality of HMOX1-deficient mice. Surviving HMOX1-null mice suffer from anemia, 
kidney iron overload and a lack of heme-recycling macrophages137. In vitro-derived 
HMOX1-null macrophages do not survive the process of erythrophagocytosis, 
therefore the lack of macrophages in vivo is presumed to be an effect of cellular heme 
toxicity137. Free heme is highly toxic and can lead to oxidative stress, hemolytic stress 
and inflammation3. Free heme provides an abundant source of redox-active iron that 
leads to the production of toxic hydroxyl (•OH) and hydroperoxyl (•OOH) radicals 
through Fenton reaction138. Free heme can also cause protein aggregation, lipid 





increase 13-linoleic acid hydroperoxide-induced lipid oxidation of human erythrocyte 
ghost, which leads to membrane instability139. Hemin also catalyzes the oxidative 
degradation of proteins140 and causes DNA damage. Hemin-induced reactive oxygen 
species (ROS) attacks DNA, causing nicking of supercoiled DNA into open and 
linear forms and subsequent degradation of the linear DNA141. The hydrophobic and 
lipophilic nature of heme allows it to readily intercalate into cellular membranes  and 
subsequent oxidation of the cell membrane by iron promotes the formation of lipid 
peroxide leading to cell membrane permeabilization and cell death3. The occurrence 
of this process in RBCs can be highly detrimental and cause hemolysis. Heme 
intercalation into erythrocyte membranes impairs the maintenance of cellular cation 
gradients and induces hemolysis by a colloid-osmotic mechanism142. Heme-induced 
hemolysis begins with massive loss of cellular potassium, glutathione and ATP, 
followed by loss of hemoglobin142. Hemin membrane insertion completely disrupts 
red cell ghosts, impairing lipid and protein associations143. Systemically, free hemin 
promotes inflammation through activation of innate immunity cells and non-
hematopoietic cells. Heme induces leukocyte migration along the vasculature by 
inducing expression of adhesion molecules ICAM-1 (intercellular adhesion molecule 
1), VCAM-1 (vascular cell adhesion molecule 1), E-selectin, P-selectin, and von 
Willebrand factor of endothelial cells144,145. Hemin injections into rats caused the 
activation of neutrophils, resulting in neutrophilic expression of adhesion molecules 
and subsequent neutrophil migration from intravascular sites to tissue parenchyma146. 
Heme can also act as a chemotactic molecule to cause neutrophil migration147. In 





production by both endothelial cells and neutrophils146,148. Heme-induced pro-
inflammatory cytokine production is also evident in macrophages. Macrophages are 
activated by heme and as a result secrete pro-inflammatory molecules such as TNF, 
KC (keratinocyte-derived chemokine)149, IL-1β150 and LTB4 [lipid mediator 
leukotriene B(4)]151. These molecules not only activate and attract leukocytes to sites 
of inflammation, but also regulate cell death and increase vascular endothelial 
permeability, enhancing the inflammatory response150. 
Heme also induces HMOX1 expression, which degrades heme and produces 
anti-oxidants, cytoprotective and anti-inflammatory molecules like CO and bilirubin. 
HMOX1 is therefore often an acute phase response protein. Bilirubin, an anti-oxidant 
product of heme degradation, scavenges peroxyl radicals and inhibits lipid 
peroxidation, conferring protection against inflammation152. CO dampens 
inflammation by inhibiting expression of TNF, IL-1β and macrophage inflammatory 
protein-1β via a MAPK (mitogen-activated protein kinase) signaling pathway153. 
HMOX1 induction also stimulates ferritin synthesis, which increases the scavenging 
of free iron, protecting cells from cytotoxic effects of free iron154. As such, HMOX1 
is important in mediating anti-inflammatory and protective effects during heme 
release. 
Heme toxicity and detoxification in parasites 
Hematophagous parasites (or hemoparasites) such as the malarial parasite 
Plasmodium and digenean Schistosoma utilize the host blood as a comprehensive 
source of nutrients including iron and heme155. The adoption of hematophagy to 





heme biosynthetic pathway in these parasites156. For example, hematophagous 
nematodes (including Ancylostoma caninum, Haemonchus contortus, Ascaris suum), 
digenean Schistosoma mansoni and the tick Rhipicephalus microplus lack enzymatic 
activities for ALAD, PBGD and FECH, which indicate complete loss of de novo 
heme biosynthesis156,157. Other parasites such as the trypanosomatid Leishmania spp. 
have a partially functional heme biosynthetic pathway, with only the last three 
enzymes of the pathway being present and functional while Trypanosoma cruzi and 
the filariid nematode Brugia malayi lack the heme biosynthetic pathway158,159. 
Plasmodium falciparum and Plasmodium berghei, which live within the host’s 
erythrocytes, have been shown to synthesize heme de novo by utilizing host heme 
biosynthetic enzyme ALAD trafficked from erythrocytes160. The trafficked host 
enzymes contribute to ~80% of the parasite heme biosynthesis, and inhibition of host 
ALAD trafficking results in the death of intra-erythrocytic Plasmodium parasites as it 
becomes incapable of meeting the requirement for heme-dependent protein 
synthesis161. However, these parasites still largely depend on ingestion of host 
hemoglobin for heme and iron. Due to the levels of ingested heme, these 
hemoparasites are constantly exposed to intracellular heme toxicity, necessitating an 
efficient heme excretion and detoxification pathway. Although some hemoparasites 
including  Rhodnius prolixus163 appear to have HMOX-like enzymes that may 
catabolize ingested heme, some hemoparasites commonly utilize the conversion of 
heme into an inert crystalline structure called hemozoin to prevent heme toxicity164. 
This detoxification pathway involves the crystallization of α-hematin 





which is chemically identical to β-hematin and has paramagnetic properties165. Using 
multi-frequency high-field electron paramagnetic resonance (HFEPR), Hz was 
observed to contain five coordinate high spin trivalent Fe3+ compounds and within Hz 
the iron atom is attached by ionic bonds to the four adjacent nitrogen atoms of the 
porphyrin166. While the mechanisms of parasitic in vivo Hz formation remain 
unresolved, it has been shown that heme polymerization into Hz is a chemical process 
that can occur in the absence of proteins, indicating that it does not have to be an 
enzyme-mediated process167. β-hematin formation in acidic acetate solution is 
dependent on a moderately low pH (5-6) but spontaneous168, and the conditions 
appear to parallel the microenvironment of Hz production in vivo. The digestive 
vacuole of Plasmodium sp. in which Hz is formed has a pH ranging from 4.2 to 5.9169 
while the pH of the gut of Schistoma sp. where Hz is produced is maintained below 
pH 5170.  
Although β-hematin can be synthesized in vitro to yield the same NMR 
(nuclear magnetic resonance) and X-ray diffraction as naturally formed Hz, the size 
and shape of β-hematin crystals are not identical to that of Hz. Natural Hz crystals are 
typically smaller (50-500 nm) and β-hematin crystals range from 50 nm to 20 μm164. 
The shape and size of Hz crystals also vary between specific Plasmodium sp. 
parasites and other Hz-producing hemoparasites171, although the basis of this 
diversity is still unknown. 
Problem Statement 
Heme-iron recycling by reticuloendothelial macrophages account for ~50% and 





heme is more readily absorbed than inorganic iron11,12. Consequently, genetic 
ablations of HMOX1, FLVCR, DMT1, ferroportin, and ferritin in mice have all 
resulted in partial or complete embryonic lethality, underscoring the importance of 
heme-iron recycling to systemic iron metabolism. HRG1 was first identified as a 
heme transport protein in C. elegans and the mammalian homolog was later shown to 
transport heme across the phagosomal membrane during macrophage heme-iron 
recycling. Since the NRAMP1-deficient mouse does not show any overt deficiencies 
in heme-iron recycling, the in vivo role of HRG1 and transport of heme derived from 
erythrophagocytosed RBCs remains an open question.  Will the genetic ablation of 
HRG1 result in embryonic lethality, similar to the other genes in heme-iron 
recycling? Does heme transport on the apical surface of enterocytes also mediated by 
HRG1? In this work, we show that a genetic mouse model of HRG1-deficiency is 
incapable of recycling erythrocyte heme-iron and shows high tolerance to heme 
through the formation of inert crystalline hemozoin. HRG1-deficient mice are also 
abnormal in iron metabolism signaling in response to systemic iron-deficiency, 
leading to death.  Further, we explore whether HRG1 also functions as an intestinal 





Chapter 2 : Materials and Methods 
Mouse-related methods 
Animals 
All mice used were housed in a 12 hour light-dark cycle.  Genetic segregation 
was computed on 21-day old (P21) mice pups.  HRG1 mice were genotyped from tail 
genomic DNA extracts using a custom ordered TaqMan® SNP Genotyping Assays 
probe (ThermoFisher Scientific) on a Bio-rad CFX Connect system.  Mice in all 
studies were males unless otherwise noted, although initial experiments to exclude 
gender variation were done using both males and females.  All animal protocols were 
approved by the Institutional Animal Care and Use Committee at the University of 
Maryland, College Park. 
Generation of HRG1-/- mice 
Guide and Cas9 RNAs: The guide RNA (5'-
TAGGGACGGTGGTCTACCGACAACCGG-3') was purchased from Sage 
Laboratories, St Louis, MO. Cas 9 RNA was purchased from Trilink Biotechnologies, 
San Diego, CA. The guide RNA and Cas9 RNA were combined at a concentration of 
5 ng/µl each in 10 mM Tris, 0.25 mM EDTA (pH 7.5) for injection. 
Pronuclear injection was performed using standard procedures173.  Briefly, 
fertilized eggs were collected from superovulated C57BL/6J x 129/SvJ F1 females 
approximately 9 hours after mating with C57BL/6J male mice.  Pronuclei were 
injected with a capillary needle with a 1-2 µm opening pulled with a Sutter P-1000 





continuous flow estimated to deposit approximately 2 pl of solution.  Injected eggs 
were surgically transferred to pseudo-pregnant CB6 F1 recipient females. (The 
pronuclear injections were conducted by Ms. Lisa Garrett, National Human Genome 
Research Institute.) 
DNA was obtained from founder (F0) animals by tail biopsy, amplified by 
PCR (Forward 5’-TGCACCTGTGACTCGGCG-3’ Reverse 5’-
TAGGTCCCGCCACGTTCATAA-3’) and sequenced to determine the mutation.  F0 
animals carrying mutations were crossed to C57BL/6 animals and the resulting 
heterozygous F1 animals were either intercrossed to generate homozygous mutant 
animals or back crossed to C57BL/6 mice for propagation. (The sequencing of 
mutants and maintenance of initial colony were conducted by Mr. Will Simmons, 
National Human Genome Research Institute.) 
Dietary study 
HRG1+/+ and HRG1-/- mice obtained from HRG1+/- crosses were weaned at 21 
days of age (P21) and placed on their respective diets, supplemented with deionized 
water.  Standard rodent diet was obtained from Envigo and the 2 ppm (TD.09127) Fe 
diet was custom ordered from Envigo, Madison, WI.  Blood was collected by retro-
orbital bleeding using microcapillary tubes (Fisher Scientific, cat. number 22-
362566).  At the end of 5 weeks, mice were sacrificed by cardiac perfusion using 
Dulbecco's phosphate-buffered saline (DPBS) (Gibco, cat. number 14190250) under 
anesthesia (10% ketamine, 8% xylazine mix).  Prior to perfusion, whole blood was 
collected into tubes and allowed to clot at room temperature for 45 minutes and serum 





Histology and immunohistochemistry 
Paraffin-embedded tissue sections were processed for antigen retrieval by 
heat-induced epitope retrieval in citrate buffer pH 6 (DAKO, Glostrup, Denmark, cat. 
number S2367).  After epitope retrieval, sections were then incubated with either rat 
anti-F4/80 (Invitrogen, cat. number MF48000) (1:1000 in blocking buffer TBS with 
2% FBS) or rabbit anti-HRG1174 (1:500) overnight at 4°C. Polyclonal HRG1 
antibody serum was generated in rabbit using the C-terminal 17 amino acid peptide 
sequence (YAHRYRADFADIILSDF) of human HRG1 as antigen (Epitomics, Inc.). 
Sections were then incubated with secondary biotinylated anti-rat antibody (Vector 
labs, cat. number BA-9400) for 30 minutes at room temperature.  Signals were 
detected by DAB substrate incubation and slides were lightly counterstained with 
hematoxylin. 
Crude membrane preps and HRG1 immunoblots 
Tissues were snap frozen in liquid nitrogen and ground up using a ceramic 
pestle and mortar maintained ice-cold.  In a dounce homogenizer, ground tissue 
samples were added to membrane prep buffer (250 mM Sucrose, 1 mM EDTA, 10 
mM Tris-HCl pH 7.4, 3X protease inhibitor cocktail).  Samples were dounce 
homogenized until no obvious chunks of tissue were observed and the number of 
strokes used for homogenization was kept consistent across all samples.  
Homogenates were centrifuged at 800 g for 10 minutes at 4°C.  The supernatant was 
transferred to ultracentrifugation tubes and spun at 100,000 g for 2 hours at 4°C.  The 
pellet from ultracentrifugation was then resuspended in lysis buffer (150 mM NaCl, 1 





sonicated to ensure complete solubilization.  The sample was then centrifuged at 
11,000 g for 30 minutes at 4°C and the insoluble pelleted debris was discarded.  
Protein concentration of the supernatant was determined using the BCA assay 
(Pierce™ BCA Protein Assay Kit, ThermoFisher Scientific, cat. number 23225).  
Samples were mixed with Laemmli sample buffer without heating, separated on a 4–
20% Criterion™ TGX™ Precast Midi Protein Gel (Bio-rad, cat. number 5671094) 
and transferred to nitrocellulose membrane.  Proteins were cross-linked to membranes 
by UV treatment and stained by ponceau S before incubation in blocking buffer (5% 
nonfat dry milk in 0.05% PBS-Tween 20, PBS-T) for 1 hour at room temperature.  
Blots were then incubated overnight at 4 °C in blocking buffer containing rabbit anti-
HRG1 antibody (1:300 dilution).  After three washes in PBS-T, blots were incubated 
1 hour with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary 
antibody (1:20,000; Invitrogen cat. number 31460) in blocking buffer.  Blots were 
then washed five times with PBS-T and signals were visualized by using enhanced 
chemiluminescence (SuperSignal West Pico, Pierce) and detected using ChemiDoc™ 
Imaging Systems (Bio-rad). 
RNA extraction and quantitative reverse-transcriptase PCR 
Total RNA was isolated from samples using TRIzol™ Reagent 
(ThermoFisher Scientific).  cDNA synthesis was done using RT2 First Strand Kit 
(Qiagen). The Qiagen iron metabolism RT2 profiler array (cat. number 25204D) was 
custom built and used with RT2 SYBR Green Fluor qPCR mastermix (Qiagen) on a 
CFX Connect system (Bio-rad).  Analysis of gene expression data was conducted 





each gene in each group (eg. +/+, Standard diet) were obtained by taking the average 
across all mice (n=9 per group). ΔCt values were then obtained by the following 
formula: ΔCt = Ct (target gene) – Ct (housekeeping gene). The housekeeping gene 
used was Rpl13a. Gene expression was then calculated by the formula 2^(- ΔCt).  p-
values for gene expression were calculated using ΔCt values, the corresponding 
standard deviations and n=9.  The gene expression heatmap was generated by the 
Heatmapper software and clustering was performed using Pearson’s distance 
measurement method with average clustering175. 
X-ray fluorescence microscopy 
Sample preparation was performed as described previously176. Briefly, 
macrophages were cultured directly onto sterilized silicon nitride membranes (1.5 x 
1.5 mm, SiN, Silson Ltd, Northhampton, England) that had been incubated with 
sterile 0.01% Poly-L-lysine solution (Sigma-Aldrich, St Louis, MO). For the XFM 
experiments, the cells on the SiN membranes were fixed with 4% paraformaldehyde 
(PFA), rinsed sequentially with PBS, isotonic 100 mM ammonium acetate, DI water 
and air-dried.  
XFM data were collected on the Bionanoprobe177, beamline 9-ID-B, at the 
Advanced Photon Source, Argonne National Laboratory, Argonne, IL. The incident 
X-ray energy was tuned to 10 keV using a Si-monochromator, the monochromatic 
beam was focused to 80 x 80 nm using a Fresnel zone plate. The sample was placed 
at 15˚ to the incident X-ray beam and the resulting X-ray fluorescence was collected 
at 90º using an energy dispersive 4-element detector (Vortex ME-4, SII 





background subtracting, and fitting the fluorescence counts for each element at each 
point using the program MAPS178. The fluorescent photon counts were translated into 
µg/cm2 using calibrated X-ray standards (AXO products, Dresden, Germany). (The 
XFM experiments were conducted by Dr. Martina Ralle, Oregon Health Sciences 
University.)  
X-ray powder diffraction analysis 
The powder samples were mounted in a 0.4 mmφ glass capillary. The X-ray 
powder diffraction data were measured using a large Debye-Scherrer camera with an 
imaging-plate as a detector installed at SPring-8 BL02B2179. The wavelength of 
incident X-ray was 0.800 Å. The exposure time was 17min. The X-ray powder 
diffraction patterns were collected in 0.01° steps in 2θ. The data range of the present 
analysis was from 2.0° to 30.0° in 2θ, which corresponds to more than 1.55 Å in d-
spacing range. Peak positions and relative intensities of powder profile were similar 
to those of β-hematin180. The rigid-body Rietveld analysis was carried out as an initial 
stage of refinement using the program SP181. The reliability factors of final Rietveld 
refinement were Rwp=2.6% and RI=5.7%, respectively. (The X-ray diffraction 
analyses were conducted by Dr. Hiroshi Sugimoto, RIKEN, Spring-8, Japan.) 
Inductively coupled plasma mass spectrometry (ICP-MS) 
Prior to metal and heme analyses, frozen tissues were added to three volumes 
of pure water and homogenized in ceramic bead tubes (Qiagen) using an Omni Bead 
Ruptor 24. For metal analysis, homogenate aliquots were digested overnight in 5:1 





ICP-MS. Calibration standard solutions for determination of Fe, Zn, Cu & Mn were 
prepared from Agilent multi-element calibration standard-2A. Protein concentrations 
of homogenates were determined by BCA Protein Assay (Thermo Fisher Scientific) 
for normalization. (The ICP-MS samples were analyzed by Dr. Laurie Jackson, 
University of Utah.) 
Porphyrin extraction 
Enough tissue homogenate preparation for ICP-MS was adjusted with water to 
make 50 µL of 5 mg/mL protein. The resulting suspension was extracted with 200 µL 
of EA (a mixture of four volumes of ethyl acetate to one volume glacial acetic acid), 
centrifuged at 13.5K rpm for 0.5 minutes, and the supernatant was removed. The 
residual was re-extracted with 200 µL of water-saturated EA and centrifuged 
similarly. The two supernatants were combined to make about 400 µL total volume, 
and 10 µL of which was injected into the UPLC. 20 µL of 2xNES (0.2M NaOH, 4% 
w/v SDS and 6 mM EDTA) added to the ~20µL residual. The resulting suspension 
was slowly mixed with 280 µL EA and then centrifuged at 13.5K rpm for 10 minutes.  
10 µL of the supernatant was injected into the UPLC. In addition, 25 µL of un-
extracted homogenate was mixed with 25 µL 2xNES, then with 350 µL EA, 
centrifuged at 13.5K rpm for 10 minutes and the supernatant was analyzed by UPLC. 
(The porphyrin extraction was conducted by Mr. Hector Bergonia, University of 
Utah.) 
UPLC 
About 10 µL of sample extract was injected into a Waters Acquity UPLC 





detector (PDA), fluorescence detector (FLR), column heater and an Acquity UPLC 
BEH C18, 1.7 µM, 2.1 x 100 mm column. The PDA was set to measure hemin 
absorbance at 398 nm and the FLR to measure fluorescence of protoporphyrin IX 
(PPIX) at 404 nm excitation and 630 nm emission. Solvent A was 0.2% aqueous 
formic acid while Solvent B was 0.2% formic acid in methanol. The flow rate at 0.40 
mL per minute at 60˚C for the total run time of 7 minutes. The following successive 
gradient settings for run time in minutes versus A: 0.0, 80%; 2.5, 1%; 4.5, 1%; 5, 
80%.  The solvent composition gradient settings were all linear. For standards, 
solutions of known concentrations of authentic hemin, PPIX dissolved in NES were 
extracted and then analyzed by UPLC as the samples. (The UPLC analyses were 
conducted by Mr. Hector Bergonia, University of Utah.) 
Serum Iron panel 
Serum iron, total iron binding capacity (TIBC) and transferrin saturation were 
measured using the Stanbio Iron & TIBC kit (VWR, cat. number 10152-550). Serum 
transferrin and ferritin were quantified using the mouse transferrin ELISA kit 
(Abcam, cat. number ab157724) and mouse ferritin ELISA kit (Abcam, cat. number 
ab157713). All kits were used according to the manufacturer’s protocol. 
Serum EPO and Hepcidin 
Serum erythropoietin (EPO) was measured using the mouse erythropoietin 
quantikine ELISA kit (R&D Systems, cat. number MEP00B). Serum hepcidin was 
measured using the Hepcidin Murine-Compete™ ELISA Kit (Intrinsic Life Sciences, 





59Fe-labelled erythrocytes preparation 
59FeCl3 purchased from Perkin Elmer Life Sciences (cat. number 
NEZ037001MC) was mixed with sodium citrate (1:50 molar ratio in a total volume of 
1 mL) and incubated for 1 hour at room temperature to make 59Fe-citrate. To generate 
59Fe-labelled RBCs, adult mice were first injected intraperitoneally once per day for 3 
consecutive days with 50 mg/kg of phenylhydrazine (Sigma Aldrich, cat. number 
114715) to induce anemia. Thirty minutes after the last phenylhydrazine dose, the 
mice were injected intraperitoneally with 200 μL of radiolabeled 59Fe-citrate (0.03 
μM, ~12 million cpm). Following a 3-day rest, the mice were anesthetized (10% 
Ketamine with 5% Xylazine) and whole blood was collected by retro-orbital bleeding 
using heparinized tubes. Whole blood was mixed with an equal volume of Alsever’s 
solution (Sigma Aldrich, cat. number A3551). Mice were then sacrificed by cervical 
dislocation. 59Fe-RBCs were collected by centrifugation, washed with DPBS before 
counting, and opsonized with the mouse RBC antibody (Rockland, cat. number 210-
4139); 20 μL of antibody was used for approximately 109 RBCs. The suspension was 
diluted to 10 mL with PBS, and incubated at 37°C on a rotating table for 20 minutes. 
The opsonized cells were washed twice with DPBS and counted again.  
59Fe-RBC in vivo Recycling 
Opsonized 59Fe-RBCs were diluted with DPBS and injected intraperitoneally 
into iron-deficient HRG1+/+ and HRG1-/- mice (250 µl, 860,000 cpm per mouse). 
59Fe-RBCs-injected mice provided with food and water were sacrificed by CO2 
asphyxiation at 24 and 96 hours post-injection. Whole blood was collected retro-





homogenates were collected on a Perkin Elmer (Packard) Wizard gamma counter and 
whole carcass counts were collected using a Model 2200 scalar ratemeter (LUDLUM 
measurements, Inc, Sweetwater, TX). 
To count for 59Fe in different extracts in spleens, spleens from the 96-hour 
time-point were dounce homogenized in lysis buffer (1% Triton X-100, 1% 
proteinase K, Tris-HCl pH 8.0, 50 mM NaCl, 5 mM CaCl2) and incubated overnight 
at 37°C. One-third of the homogenate was centrifuged at 11,000 g for 45 minutes to 
obtain the insoluble fraction. Ethyl acetate (EA) (1 part glacial acetic acid, 4 parts 
ethyl acetate) was added to the supernatant (1 part supernatant, 4 parts EA). The 
suspension was vortexed for 1 minute and centrifuged at 800 g for 2 minutes to 
separate the organic and aqueous phase. This extraction was repeated once to the 
aqueous layer and EA extracts were pooled for counting. 
59Fe gavage and intravenous injection 
Prior to 59Fe gavage experiments, mice were fasted overnight but provided 
with water. Each mouse was gavaged with (volume ~250 μL) 5 μCi 59Fe in a solution 
containing 0.5 M ascorbate, 0.15 M NaCl and 5 μg FeSO4. For 7 hours post-gavage, 
mice were provided with only water, with food being provided after the 7 hours. For 
intravenous (IV) 59Fe injections, each mouse was injected IV through the retro-orbital 
sinus under anesthesia. The solution injected contains 5 μCi 59Fe in a citrate buffer 
(pH 6.6) and either 5 µg or 70 μg iron (non-transferrin bound iron experiment). Mice 
were sacrificed by CO2 asphyxiation 24 hours post-gavage or IV injections and 
organs were dissected for 59Fe counting. For bone marrow, one femur and tibia were 





gamma counter and whole carcass counts were collected using a Model 2200 scalar 
ratemeter (LUDLUM measurements, Inc, Sweetwater, TX).  
In vivo RBC lifespan measurement 
RBC lifespan was determined by labeling RBCs with sulfo-NHS-biotin 
reagent (Pierce, Rockford, IL). Mice were injected intravenously under anesthesia via 
the retro-orbital sinus with 1 mg of sulfo-NHS-biotin. At different time points post 
injection, 5 μL of blood was obtained from the tails and resuspended in 300 µl DPBS. 
The blood samples were stained with Streptavidin, R-Phycoerythrin Conjugate 
(Invitrogen, cat. number S866) and allophycocyanin (APC)-conjugated Ter-119 
(eBioscience, cat. number 47-5921-82) and analyzed by flow cytometry.  
In vivo depletion of macrophages 
To deplete macrophages in vivo, control of clodronate liposomes (Liposoma, 
cat. number CP-005-005) were administered intravenously via the retro orbital sinus 
of mice under anesthesia. A solution of 5 mg/mL clodronate liposomes was used and 
0.01 mL/g body weight of liposomes was injected per mouse. Hematocrit was 
measured on the indicated dates and mice were sacrificed on the indicated days by 
cardiac perfusion under anesthesia. 
Hemozoin extraction and quantification 
Hemozoin extraction was performed according to the method of Deroost et 
al182. Approximately 50 to 100 mg perfused mouse liver or spleen were ground in 
liquid nitrogen with mortar and pestle. The ground powder was resuspended in five to 





mM NaCl, 1% Triton X-100 and 1% Proteinase K) and incubated overnight at 37°C 
with gentle shaking. For mice younger than three weeks, a whole liver or spleen was 
homogenized in minimum five volumes of homogenization buffer using FastPrep-24 
(MP Bio) for 30 seconds at the 6.5 m/s setting, followed by overnight incubation at 
37°C with gentle shaking. The proteinase K digested homogenate was then sonicated 
(Heat Systems-Ultrasonics, W350) for 1 minute (20 W, pulse 1 sec) and centrifuged 
at 11,000 g for 45 minute. The supernatant was collected in a new tube (fraction 
Supernatant) and the pellet was washed three times in washing buffer (100 mM 
NaHCO3, pH 9.0 and 2% SDS) with 1 minute sonication and 30 minutes 
centrifugation at 11,000 g. All the supernatant from three wash steps was collected 
and combined (fraction Washing). The remaining pellet (Hz, fraction Pellet) was 
dissolved and sonicated for 1 minute in dissolving buffer (100 mM NaOH, 2% SDS 
and 3 mM EDTA) and centrifuged at 11,000 g for 30 minutes to discard any 
insolubles. For X-ray powder diffraction analysis, after the third wash, extracted Hz 
was washed five more times in distilled H2O to remove the salts and detergents. 
Heme concentrations of all three fractions (Supernatant, Washing and Pellet) 
were determined by pyridine hemochromogen spectra method183. A pyridine reagent 
mix was prepared by adding 3 mL 1 M NaOH and 6 mL pyridine to 19 mL H2O in a 
glass container. For oxidized spectrum, 35 μL sample and 17 μL 15 mM K3Fe(CN)6 
was mixed with 1 mL pyridine reagent in a cuvette and the spectrum at 400-675 nm 
was recorded (Shimadzu, UV-1601). Few crystals (2 – 5 mg) of powdered Na2S2O4 
were then added to the mixture and the reduced spectrum was recorded at 400-675 





541, 556 and 575 nm in the oxidized spectrum from the corresponding readings in the 
reduced spectrum to get ∆A540, ∆A556 and ∆A575, using the extinction coefficients 
20.7 / mM for ∆A540 ((∆A556 - ∆A540) / 20.7) and 32.4 / mM for ∆A575 ((∆A556-
∆A575) / 32.4), multiplying by the dilution factor of the sample (30.06 or (1000 + 35 
+ 17) / 35) and averaging the two results. Total heme (nmol / mg tissue) in each 
fraction was calculated by multiplying heme concentration with corresponding 
fraction volume, and then divided by the weight of homogenized tissue. Total heme 
(nmol / organ) in each fraction was calculated by multiplying total heme (nmol / mg 
tissue) with the total weight of corresponding organ. Total heme in the Supernatant 
and Washing fractions was summed up as non-Hz heme. 
Iron-deficient mice 
HRG1+/+ and HRG1-/- mice were placed on the 2 ppm Fe diet post weaning 
and hematocrit was monitored weekly. The experiment was conducted when the 
hematocrits of all mice was within 40-75% of their respective starting hematocrits. 
These iron-deficient mice were used for 59Fe-gavage, in vivo recycling and in vivo 
macrophage depletion experiments. 
Spleen and bone marrow cells isolation 
Mouse spleens were cut up into 1-3 mm pieces and placed in 5 mL of 
dissociation buffer (RPMI, 1X collagenase B, 1X DNase I) in tubes with a magnetic 
stir bar. Tubes were placed on a magnetic plate and spleens were dissociated at 37°C 
for 45 minutes. Homogenates were passed through 70 μm filters and cells were 
pelleted by centrifugation at 800 g for 10 minutes. Bone marrow cells were flushed 





FACS buffer (DPBS with 2% FBS). Cell aggregates were dissociated by pipetting. 
Cell suspensions were centrifuged at 800 g for 5 minutes and supernatants were 
discarded. When RBCs were not needed for analysis, cells were resuspended in 1 mL 
of RBC lysis buffer (150 mM NH4Cl, 10 mM NaHCO3, 1.3 mM EDTA) and left at 
room temperature for 3 minutes. The lysis step was quenched by adding 5 mL of 
RPMI and cells were collected by centrifugation at 800 g for 10 minutes and 
resuspended in appropriate buffers for downstream application. 
Flow cytometry 
Prior to staining for flow cytometry, cells were resuspended in FACS buffer 
and counted to ensure that appropriate amounts of antibodies would be added. Cells 
were stained in 500 µl FACS buffer with the respective antibodies on ice for 30 
minutes. After staining, cells were centrifuged at 800 g for 5 minutes and washed 
with FACS buffer before being resuspended in FACS buffer for analysis. For 
erythroid cell populations in the spleen and bone marrow, T cells, B cells, platelets, 
megakaryocytes and neutrophils were stained with fluorescein isothiocyanate (FITC)-
conjugated-CD4 (eBioscience, cat. number 14-0041-86), CD8a (eBioscience, cat. 
number 14-0081-86), B220 (eBioscience, cat. number 14-0452-86), CD41 
(eBioscience, cat. number 14-0411-85), Gr-1 (eBioscience, cat. number 11-5931-82) 
and CD11b (eBioscience, cat. number 14-0112-86) and dump gating was used to 
exclude these cell populations during analysis. In addition, cells were stained with 
antibodies for allophycocyanin (APC)-conjugated Ter-119 (eBioscience, cat. number 
47-5921-82) and eFluor-450-conjugated CD44 (eBioscience, cat. number 48-0441-





and stained with the following antibodies: phycoerythrin (PE)-conjugated Treml4 
(Biolegend, San Diego, CA, cat. number 143304), APC-conjugated F4/80 
(eBioscience, cat. number 17-4801-80), PE-Cyanine7 (PE-Cy7)-conjugated CD11b 
(eBioscience, cat. number 25-0112-81), brilliant violet 510 (BV510)-conjugated 
MHC-II (Biolegend, cat. number 107635) and PerCP-Cyanine5.5 (PerCPCy5.5)-
conjugated Gr-1 (eBioscience, cat. number 45-5931-80). For all antibodies, 1 µl was 
used to stain 1 million cells. Samples were run in a FACS Canto II or FACS Aria 
system (BD) and analysis was performed using FlowJo software (Tree Star Inc., 
Ashland, OR). 
Gating of erythroid populations 
The gating strategy for identifying different erythroid populations was as 
described elsewhere64, using CD44 as a marker for different populations. Gating 
strategies are as shown in Figs. 3.4, 3.5. 
Primary macrophage isolation and culture 
To isolate F4/80+ macrophages from splenic and bone marrow cell 
suspensions, anti-F4/80 microbeads were used in conjunction with LS columns 
(Miltenyi Biotech, cat. number 130-110-443 and cat. number 130-042-401) according 
to the manufacturer’s protocol. To isolate monocytes from bone marrow suspension, 
the mouse monocyte isolation kit was used (Miltenyi Biotech, cat. number 130-100-
629). For bone marrow-derived macrophages, differentiation of fresh bone marrow 
cells was carried out in the presence of L929- conditioned media (LCM) as a source 
of granulocyte/macrophage colony-stimulating factor. Differentiation media 





20% heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals), 100 U/mL 
penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine (Invitrogen). L-929 cells 
were purchased from the American Type Culture Collection (ATCC). For production 
of LCM, L-929 cells were grown in the presence of RPMI 1640 supplemented with 
10% heat-inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM 
L-glutamine for 30 days. Media was collected by sterile filtration and stored at −20°C 
for later use in BMDM differentiation and culture media. 
Immunofluorescence of LAMP1 
Bone marrow isolated F4/80+ macrophages (BMMs) were seeded onto 
coverslips and fixed with 4% PFA pH 7.4 for 40 minutes on ice, then washed twice 
with DPBS. Quenching was done using 0.1 M ethanolamine for 5 minutes at room 
temperature, twice. Coverslips were washed twice with DPBS and incubated in a 
buffer containing DPBS, 3% BSA, 0.4% saponin for 20 minutes at room temperature. 
Coverslips were then incubated in a buffer containing DPBS, 1% BSA and 0.15% 
saponin for 10 minutes before incubation with the LAMP1 primary antibody 
(Developmental Studies Hybridoma Bank, cat. number 1D4B, 1:100 dilution) for 1 
hour at room temperature. Cells were then washed three times with DPBS and 
incubated with the secondary antibody in the same buffer (Invitrogen, cat. number A-
2121, 1:2,000 dilution) for 1 hour at room temperature. Coverslips were then washed 
three times with DPBS and stained with DAPI (1:30,000 dilution of 5mg/mL) for 1 
minute before mounting with Pro-long Antifade (Thermofisher, cat. number P36930). 





Mammalian cell culture methods 
Caco-2 cells and heme treatments 
All three clones of Caco-2 cells (TC7, Bbe and HTB-37) were a gift from Dr. 
James Fleet (Purdue University) and maintained in cell culture media containing 
DMEM, 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-
glutamine at 37°C supplemented with 5% CO2. For heme treatments, cells were 
treated with basal media or heme-depleted (HD) media for 24 hours and the indicated 
heme concentrations were added to HD media. Cells were harvested 24 hours later 
and lysed with lysis buffer containing 1% Triton X-100 for immunoblotting protein 
analysis. 
Generation of HRG1-knockout Caco-2 cells 
To generate HRG1-knockout Caco-2 cells by CRISPR-Cas9, plasmids 
containing the guide RNA target sequences of HRG1 (APPENDIX I) (plasmid 
pSpCas9(BB)-2A-GFP, Addgene; Plasmid #48138) were transfected into unpolarized 
Caco-2 cells using PolyJet transfection reagent (Signagen, cat. number SL100688). 
Cells expressing high GFP levels were sorted out using flow cytometry (BD FACS 
ARIA II) and individual cells were seeded into 96-well plates. Surviving clones were 
expanded and screened for loss of HRG1 protein by protein immunoblots. Clones 
confirmed to have loss of HRG1 protein were then genotyped to identify the genetic 





HRG1-GFP lentiviral transduction of Caco-2 cells 
For lentiviral production of HRG1-GFP, the protocol published by The Broad 
Institute was used184. HEK293T cells maintained in DMEM, 10% FBS, 100 U/mL 
penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine at 37°C supplemented 
with 5% CO2 were first transfected with the lentiviral plasmid expressing HRG1-
GFP (Backbone: pLenti CMV/TO eGFP Puro (w159-1), Addgene, plasmid #17481) 
and packaging plasmids using standard transfection reagent PolyJet (Signagen, cat. 
number SL100688). Media containing viral particles were collected for a period of 
three days and centrifuged at 100,000 g to concentrate viral particles. Polybrene was 
added to media of Caco-2 cells at a concentration of 8 μg/mL and virus was added for 
infection.  
Caco-2 cells polarization 
To generate a monolayer of polarized Caco-2 cells, cells were seeded onto cell 
cultured inserts (Corning, cat. number CLS3412) and allowed to reach confluency. 
The Caco‐2 cell monolayer integrity was checked by measuring the transepithelial 
electrical resistance (TER) using a Millicell‐ERS device (Millipore, Bedford, MA, 
USA). Monolayers were considered polarized and used for experiments when TER 
values were in a range of 300–450 Ωcm2. 
Immunofluoresence of Caco-2 cells 
Caco-2 cells were fixed with 4% PFA, pH 7.4 for 45 minutes and quenched 
with 0.1 M ethanolamine for 5 minutes, twice. Permeabilization was done using 0.1% 
Triton-X 100 in DPBS solution for 10 minutes at room temperature. Blocking was 





(Abcam, cat. number ab76055, 1:1,000 dilution) or HRG1 antibody was applied to 
cells in blocking buffer for 1 hour at room temperature. Cells were then washed three 
times with DPBS and incubated with the secondary antibody in the same buffer for 1 
hour at room temperature. Coverslips or transwell membranes were then washed three 
times with DPBS and stained with DAPI (1:30,000 of 5mg/mL) for 1 minute before 
mounting with Pro-long Antifade (Thermofisher, cat. number P36930). 
RNA extraction and quantitative reverse-transcriptase PCR array 
Total RNA was isolated from samples using TRIzol™ Reagent 
(ThermoFisher Scientific).  cDNA synthesis was done using RT2 First Strand Kit 
(Qiagen). Primers for -HMOX1 and β-ACTIN listed in APPENDIX II were used with 
the RT2 SYBR Green Fluor qPCR mastermix (Qiagen) on a CFX Connect system 
(Bio-rad).  Technical triplicates were ran for each sample and Ct values were 
normalized to actin. 
Pigs methods 
Animals 
Weanling 21-day old piglets used in dietary study were obtained from 
Virginia Tech. University Farms and housed in a 12 hour light-dark cycle. Pig diets 
(iron-deficient, hemin-supplemented and iron-supplemented) were custom purchased 
from Envigo, Madison, WI. All animal protocols were approved by the Institutional 







21 day old weanling piglets were housed and fed with either of the three diets 
(Hybrid Fe Deficient Weaning Swine Diet TD.150872.PWD, Hybrid Hemin Weaning 
Diet (75 ppm Fe) TD.150873.PWD, Hybrid FeSO4 Weaning Diet (75 ppm) 
TD.150874.PWD) and deionized water. Feed intake was ad libitum and blood was 
drawn via the jugular vein weekly and analyzed using the Procyte Dx hematology 
analyzer (IDEXX). Pigs were euthanized by a penetrating captive bolt to the brain 
followed by immediate exsanguination. Tissues were collected and snap frozen in 
liquid nitrogen. Intestinal tissues were collected by scraping of the epithelial layer. 
(The pigs were maintained and monitored by Ms. Elda Kwong and Ms. Abisha 
Dowla, University of Maryland.) 
Immunoblots of pig tissues 
Samples were processed in a similar manner as mouse tissues using crude 
membrane preparation as mentioned previously. 
Statistical analyses 
All data are shown as means ± SEM unless otherwise stated. Means of groups 
were compared by using Student’s unpaired t test or the equivalent where applicable. 
A p value of <0.05 was considered statistically significant.  Analyses were performed 






Chapter 3 : HRG1-deficiency results in a macrophage heme-iron 
recycling defect 
Summary 
Cell biological studies in bone marrow derived macrophages have 
demonstrated that HRG1 transports heme from the endolysosomal lumen into the 
cytosol post erythrophagocytosis109. Here we show that unlike the ablation of other 
components of the heme-iron recycling pathway, loss of HRG1 does not result in 
embryonic lethality but instead have enlarged spleens and darkened RES tissues 
(spleen, liver, bone marrow). HRG1-/- mice exhibit ineffective bone marrow 
erythropoiesis resulting in a reduced hematocrit and extramedullary splenic 
erythropoiesis. In vivo erythrophagocytosis experiments using 59Fe-labelled RBCs 
reveal that HRG1-/- mice are defective in heme-recycling, which results in heme 
accumulation in the form of hemozoin in enlarged lysosomes of RES macrophages. 
Importantly, this hemozoin is not a bioavailable source of heme or iron because 
liposome-clodronate mediated depletion of macrophages simply redistributed 
hemozoin by reducing it in the spleen and concurrently accumulating in the liver. 
These results indicate that formation of mammalian hemozoin is a mechanism of 
tolerance to cellular heme sequestered in an inert form within a membrane-enclosed 






HRG1-/- mice are viable but exhibit darkened RES tissues 
HRG1 mutant mice were generated using guide RNAs targeted to exon 1 of 
SLC48A1 (Fig. 3.1A), DNA sequencing revealed the mutation to be a two nucleotide 
deletion in the first exon of SLC48A1 gene loci encoding HRG1 protein (Fig. 3.1B). 
The mutation causes a frameshift in the region coding for the first exoplasmic (E1) 
loop of HRG1 protein (Fig. 3.1C).  Although full length HRG1 mRNA is still 
detectable (Fig. 3.1D), no HRG1 protein was observed on immunoblots of tissues 
(Fig. 3.1E).  Intercrossing heterozygous (HRG1+/-) mice revealed expected 
Mendelian distribution of their progeny (Fig. 3.1F). In adult HRG1-/- mice, the major 
reticuloendothelial system (RES) organs (spleen, liver and bone marrow) were darker 
in color compared to HRG1+/+ littermates (Fig. 3.2A) and this discoloration continues 
into old age (Fig. 3.2B). Immunohistochemistry of HRG1-/- tissue sections showed no 






Figure 3.1 Generation of HRG1-/- mouse 
(A) Gene loci of HRG1 indicating the CRISPR target site in exon 1 and mutation.  
(B) DNA sequence of HRG1+/+, HRG1+/- and HRG1-/- mice indicating sequence 
mutation.  
(C) Predicted topology of HRG1 protein; arrow indicates the site of the 2 basepair 
deletion resulting in frameshift mutation.  
(D) Amplification of HRG1 open reading frame from mouse spleen cDNA.   





(F) Immunoblotting analysis of membrane lysates prepared from spleens and livers of 
mice. Membranes were probed with anti-HRG1 antibody and then incubated with 







Figure 3.2 HRG1-/- RES tissues are discolored and contain dark pigments 
(A) Representative images of spleens, livers and bone marrows of 6-week old sex-
matched mice.  
(B) Representative images of spleens, livers and bone marrows of 12-month old sex-
matched mice.  
(C) HRG1 immunohistochemistry analysis of paraffin-embedded tissue sections of 
mice. Tissue sections were probed with affinity-purified anti-HRG1 antibody and 
then incubated with HRP-conjugated anti-rabbit secondary antibody. Images shown 





(D) Histochemical staining of spleen, liver and bone marrow tissue sections of 
HRG1+/+ and HRG1-/- mice with H&E. Arrows indicate dark pigments in HRG1-/- 






HRG1-/- mice have enlarged spleens and reduced hematocrits 
Spleens of adult HRG1-/- mice were significantly heavier than HRG1+/+ spleens with 
no difference in the total body weights or weights of other organs of these mice (Fig. 
3.3A, B). Four-week old HRG1-/- mice also exhibited significantly lower whole blood 
hematocrit levels (Fig. 3.3C). Enlarged spleens and reduced hematocrits were also 
observed in 24-month old HRG1-/- mice but not HRG1+/- mice (Fig. 3.3D-F). At nine 
weeks of age, other hematological parameters of HRG1-/- mice were not significantly 






Figure 3.3 HRG1-/- mice have enlarged spleens and lower hematocrits 
(A) Spleen wet weights from nine-week old HRG1+/+ and HRG1-/- mice.  
(B) Wet weights of liver, kidneys, heart, brain and body weights from HRG1+/+ and 
HRG1-/- mice (n=14-20).  
(C) Hematocrits of four-week old HRG1+/+ and HRG1-/- mice.  





(E) Wet weights of liver, kidneys, heart, brain and body weights from HRG1+/+, 
HRG1+/- and HRG1-/- mice (n=6-7).  
(F) Hematocrits of 24-month old HRG1+/+, HRG1+/- and HRG1-/- mice (n=6). Where 







Table 3-1. Hematological parameters of 10-week old HRG1+/+ and HRG1-/- mice 
 
Standard diet 2ppm diet* n 
 
+/+ -/- +/+ -/- 
 
HCT (%) 50.06±1.125a 48.81±1.018a 32.84±2.227b 27.94±2.178b 8-15 
RBC 
(M/μL) 
10.08±0.2372a 9.942±0.1932a 8.034±0.5503b 6.982±0.557b 8-15 
MCV (fl) 49.7±0.2252a 49.07±0.2831a 40.88±0.4719b 40.14±0.4421b 8-15 
RET (%) 4.324±0.2885a 4.204±0.1289a 3.662±0.7153b 4.337±0.6404b 8-15 
HGB (g/dl) 12.69±0.3232a 15.41±1.411a 8.52±0.836b 8.16±0.9558b 8-15 
MCH (pg) 14.84±0.1253a 14.55±0.08273a 13.84±0.4104b 14.18±0.475b 8-15 
*2ppm diet indicates parameters from mice that were fed a low-iron diet for five 
weeks 






Ineffective bone marrow erythropoiesis in HRG1-/- mice results in extramedullary 
erythropoiesis 
To investigate the erythropoietic compartments, we used Ter-119 and CD44 
as erythroblastic cell surface markers64. We analyzed the total erythroid compartment 
as well as different populations of developing erythroblasts via flow cytometry in the 
bone marrow (Fig. 3.4A). Corresponding to the reduced hematocrits, HRG1-/- mice 
had significantly fewer Ter-119+ cells (Fig. 3.4B), and more cells at the basophilic 
stage (Fig. 3.4C; population II), signifying an impairment in maturation of 
developing erythroblasts. Similar analyses of erythroid cells in HRG1-/- spleens (Fig. 
3.5A) showed no difference in total Ter-119+ population (Fig. 3.5B), but significantly 
more immature Ter-119+ cells present in HRG1-/- spleens (Fig. 3.5C), indicating 
aberrant extramedullary erythropoiesis. This is reminiscent of studies in mice that 
show ineffective bone marrow erythropoiesis is often accompanied by extramedullary 
erythropoiesis in the spleen65 resulting in splenomegaly. The ineffective 
erythropoiesis is consistent with the lower hematocrit in HRG1-/- mice indicative of 
mild iron-deficiency accompanied by significantly elevated serum transferrin (~1.8 
fold; Table. 3-2).  Full serum iron panel showed comparable levels of serum iron, 
total iron binding capacity (TIBC), transferrin saturation, EPO, hepcidin, and 
hemopexin (Table. 3-2), but paradoxically higher levels of serum ferritin (~1.6-fold) 






Figure 3.4 Ineffective bone marrow erythropoiesis in HRG1-/- mice 
(A) Gating strategy of total Ter-119+ and Ter-119+ subpopulations cells in the bone 
marrow.  
(B) Quantification of total Ter-119+ cells represented as a percentage of total single 
cells* in the bone marrow (n=7-12). The %single cells* on the y-axis denote single 
cells that are negative for CD4/8/41, B220 and Gr-1.  
(C) Quantification of subpopulations of Ter-119+ cells represented as a percentage of 
total Ter-119+ cells in the bone marrow (n=7-12). At least 100,000 single cells were 







Figure 3.5 HRG1-/- mice display extramedullary erythropoiesis 
(A) Gating strategy of total Ter-119+ and Ter-119+ subpopulations cells in the spleen.  
(B) Quantification of total Ter-119+ cells represented as a percentage of total single 
cells* in the spleen (n=7-12). The %single cells* on the y-axis denote single cells that 
are negative for CD4/8/41, B220 and Gr-1.  
(C) Quantification of populations II and III of Ter-119+ cells represented as a 
percentage of total Ter-119+ cells in the spleen.  At least 100,000 single cells were 






Table 3-2. Serum parameters of 10-week old HRG1+/+ and HRG1-/- mice 
 




Serum Iron (μg/dL) 113.5±11.72 129.3±11.34 8-15 
TIBC (μg/dL) 348.4±32.1 341.8±11.62 8-15 
Transferrin saturation 
(%) 
36.05±4.452 37.35±2.601 8-15 
Ferritin (ng/mL) 369.1±57.02a 585.9±58.62b 9-15 
Transferrin (g/L) 2.796±0.2433a 4.996±0.8034b 9-15 
EPO (pg/mL) 252.8±108.4 168.7±32.05 7-10 
Hepcidin (ng/mL) 95.88±6.943 99.79±15.96 5-7 
Haptoglobin (mg/mL) Undetected Undetected 5-7 
Hemopexin (mg/mL) 1.01±0.1317 1.075±0.07541 4-9 






In vivo heme-iron recycling is impaired in the absence of HRG1 
Since HRG1 functions to transports heme from the erythrophagolysosome into the 
cytosol in macrophages109 we established an in vivo experiment to evaluate red cell 
recycling defects. We generated 59Fe-labelled erythrocytes that were opsonized and 
injected intraperitoneally (IP.) into iron-deficient HRG1+/+ and HRG1-/- mice (Fig. 
3.6A). The retention and distribution of 59Fe in various tissues were then monitored 
over time. Injected opsonized erythrocytes enter the circulation and are targeted for 
erythrophagocytosis in the spleen108. Previous reports show that opsonized RBCs are 
preferentially phagocytosed by RES macrophages and cleared post-i.p. injection108. 
Mice made iron-deficient via dietary iron limitation were used to reduce ferritin-
mediated storage of 59Fe within RPMs. At 24 hours post-injection, significantly less 
59Fe was detected only in the hearts of HRG1-/- mice (Fig. 3.6B), while 48 hours later, 
there was also no difference in 59Fe retention in all organs measured (Fig. 3.6C). 
However, 96 hours post-injection, significantly more 59Fe was detected in the spleens 
of HRG1-/- mice while significantly less 59Fe was observed in the carcasses (Fig. 
3.6D). Homogenization and high speed centrifugation of splenic tissues followed by 
differential extraction via organic phase separation revealed a proteinase-resistant 
insoluble fraction that retained more 59Fe only in HRG1-/- samples. Moreover, there 
was significantly more organic solvent-extractable 59Fe-heme in HRG1-/- spleens, but 
similar levels of inorganic-phase 59Fe in HRG1-/- and HRG1+/+ spleens (Fig. 3.7A). 







Figure 3.6 In vivo recycling of 59Fe-labelled RBCs over 96 hours 
(A) Experimental design of 59Fe labeling and in vivo recycling.  
(B-D) Quantification of 59Fe retained in tissues, represented as the ratio of the amount 
of radioactivity within an organ to that of the entire animal at 24, 48 and 96 hours 






Figure 3.7 Retention of 59Fe in differentially extracted fractions of spleen and 
liver 
(A) Spleen 59Fe retained in differentially extracted fractions at 96 h, represented as 
counts per minute.  
(B) Liver 59Fe retained in differentially extracted fractions at 96 h, represented as 
counts per minute. Total homogenate: homogenized and proteinase-treated whole 
spleen; Organic: ethyl acetate extractable 59Fe-heme; Aqueous: ethyl acetate non-
extractable 59Fe; Insoluble fraction: proteinase-insoluble fraction containing 59Fe 






HRG1-/- mice show aberrant tissue metal accumulation 
Although HRG1-/- mice had higher serum ferritin levels, an indicator of 
systemic iron overload (Table 3-2), Perls’ Prussian blue staining which detects 
ferritin-bound iron did not show visible differences between HRG1+/+ and HRG1-/- 
tissues (Fig. 3.8). As the dark pigments in HRG1-/- tissues may mask the blue staining 
of ferric iron, inductively coupled plasma mass spectrometry (ICP-MS) (in 
collaboration with Dr. John Phillips, University of Utah) was used to measure total 
tissue metal content, and ultra-performance liquid chromatography (UPLC) was used 
to measure heme levels in various tissues of HRG1+/+ and HRG1-/- mice. In RES 
tissues, HRG1-/- mice had consistently more iron (Fe) and heme, with some changes 
in manganese (Mn) and copper (Cu) levels as well (Fig. 3.9A-C, E).   In addition, 
HRG1-/- hearts had dysregulation in the levels of Fe, Cu and zinc (Zn) (Fig. 3.9A, B, 
D). Surprisingly, HRG1-/- mice show significantly lower levels of Fe in the brain (Fig. 
3.9A). These analyses were technically performed by Dr. Laurie Jackson and Mr. 
Hector Bergonia from the University of Utah. In collaboration with Dr. Hiroshi 
Sugimoto (RIKEN, Spring-8, Japan), dark pigments derived from HRG1-/- mice was 
confirmed to be hemozoin the by powder X-ray diffraction (APPENDIX III). 
Hemozoin derived from HRG1-/- spleen, liver and bone marrow showed differences in 
morphology when compared to Plasmodium hemozoin by scanning electron 
microscopy (SEM) analysis (APPENDIX IV). Extraction of dark insoluble pigments 
followed by solubilization from HRG1-/- RES tissues showed hemozoin accumulation 






Figure 3.8 Histochemical staining of ferritin-bound iron in RES tissues 
Histochemical staining of spleen, liver and bone marrow tissue sections of HRG1+/+ 
and HRG1-/- mice with Perl’s Prussian blue. Images shown are representative of at 






Figure 3.9 Tissue metal and heme concentrations of HRG1+/+ and HRG1-/- mice 
(A) Iron (Fe) levels in tissues by ICP-MS. 
(B) Copper (Cu) levels in tissues by ICP-MS. 
(C) Manganese (Mn) levels in tissues by ICP-MS. 
(D) Zinc (Zn) levels in tissues by ICP-MS. 













Figure 3.10 Quantification of hemozoin in HRG1-/- tissues 
(A) Spleen non-hemozoin heme (free) and hemozoin (insoluble fraction) 
quanitifcations. 
(B) Liver non-hemozoin heme (free) and hemozoin (insoluble fraction) 
quanitifcations. 







Hemozoin accumulates within enlarged lysosomes of HRG1-/- reticuloendothelial 
macrophages 
F4/80 or EMR1 is a cell surface adhesion EGF-GPCR family member 
restricted to mouse macrophages185. Immunohistochemistry with F4/80 antibodies on 
paraffin-embedded tissue sections revealed the localization of hemozoin to be within 
F4/80+ cells in RES tissues of HRG1-/- mice (Fig. 3.11A). We isolated F4/80+ bone 
marrow macrophages (BMMs) by antibody-specific magnetic beads separation and 
conducted immunofluorescence to determine the intracellular localization of 
hemozoin. Transmission electron microscopy showed that hemozoin localizes to a 
membrane-encapsulated compartment within HRG1-/- BMMs and spleen 
macrophages, but is absent in isolated bone marrow monocytes or in vitro bone 
marrow-derived macrophages (APPENDIX V, VI). Immunofluorescence with 
antibodies against LAMP1, a type I transmembrane glycoprotein enriched on 
endolysosomal membranes186, confirmed that the hemozoin were confined within 
LAMP1+ vesicles in HRG1-/- that were significantly larger in diameter (Fig. 3.11B, 
C). Isolated F4/80+ BMMs also contained significantly more cellular iron, through X-
ray fluorescence microscopy where the iron-laden region of interests (ROI) 
corresponded to hemozoin within the BMMs (In collaboration with Dr. Martina 






Figure 3.11 Hemozoin accumulates in LAMP1+ vesicles in HRG1-/- RES 
macrophages 
(A) F4/80 immunohistochemistry analysis of paraffin-embedded tissue sections of 
mice. Images shown are representative of at least 3 mice per genotype.  
(B) Confocal microscopy of bone marrow macrophages from HRG1+/+ and HRG1-/- 
mice probed with anti-LAMP1 antibody and secondary alexa-488 antibody. 





(C) Diameter of LAMP1+ vesicles observed in F4/80+ bone marrow macrophages. In 
both HRG1+/+ and HRG1-/- cells, the diameters of LAMP1+ structures with 
distinguishable boundaries were quantified manually by ImageJ software analysis. 







Splenic red pulp macrophages are significantly fewer in HRG1-/- mice 
Heme accumulation in cells has been reported to be associated with cellular 
toxicity137, however the detrimental effects of hemozoin on cell viability are less well 
understood187. As HRG1-/- spleens have significantly more non-hemozoin heme (Fig. 
3.10A), we wondered if the quantities of splenic red pulp macrophages (RPMs) 
would be also different in these spleens. Quantification of RPMs in HRG1-/- mice by 
flow cytometry showed significantly fewer splenic red pulp macrophages 
(F4/80hiTreml4+) than in HRG1+/+ spleens (Fig. 3.12A, B).  This was accompanied by 
an imbalance in monocyte populations quantified by the ratio of mature to immature 
monocytes.(Fig. 3.12C, D). In HRG1-/- spleens, the ratio of F4/80int to F4/80lo -
CD11bhi monocytes was significantly higher than in HRG1+/+ spleens (Fig. 3.12C, 
D). There were also fewer neutrophils (Gr-1+CD11bhi) in the spleens of HRG1-/- mice 






Figure 3.12 HRG1-/- mice have fewer splenic red pulp macrophages 
(A, C, E) Gating strategies of different splenic populations: splenic F4/80hiTreml4+ 
red pulp macrophages (RPMs), F4/80hi, F4/80lo-CD11bhi splenic monocytes and Gr-
1+CD11bhi neutrophils. 
(B, D, F) Quantification of RPMs, monocytes and neutrophils. At least 100,000 






In vivo apoptosis of HRG1-/- RES macrophages results in liver hemozoin accumulation 
Intracellular hemozoin produced by parasites is typically thought to be inert 
and human monocytes are able to ingest malarial hemozoin where the ingested Hz 
remains unmodified for long periods of time188. We wondered whether mouse Hz in 
HRG1-/- mice could be used as a source of iron when macrophages are forced to 
undergo apoptosis. To test this, we administered clodronate liposomes to HRG1+/+ 
and HRG1-/- iron-deficient mice. When administered intravenously, macrophages in 
the spleen, liver, lung and peritoneal phagocytose the clodronate-containing 
liposomes resulting in the accumulation of intracellular clodronate. This leads to 
irreversible cellular toxicity and apoptosis of macrophages in vivo189. Using this 
method, we were able to deplete splenic, liver and bone marrow F4/80+ macrophages 
in vivo (Fig. 3.13A-D). Day 3 post-injection, no F4/80 staining could be observed in 
histological sections of clodronate-treated mice spleen, liver and bone marrow (Fig. 
3.13A-C). On day 7 post-injection, partial F4/80 staining could be observed in the 
spleens, livers and bone marrows of clodronate-treated mice as compared to control 
liposome injected mice (Fig. 3.13A-C). Despite the loss of RES macrophages, HRG1-
/- spleens, livers and bone marrows still retained hemozoin, which were now extruded 
into the interstitial space (Fig. 3.13A-C, right panel, Fig. 3.14). Flow cytometry 
analysis of clodronate-treated spleens revealed significant depletion of RPMs day 7 
post-injection but RPMs were repopulated by day 14 (Fig. 3.13D).  
We reasoned that since the mice were anemic from iron-deficiency, if Hz 
released upon apoptosis of macrophages was reutilized as a bioavailable source of 





hematocrit. There was no difference in hematocrits post-clodronate administration 
(Fig. 3.15A). Total erythroid cells in the bone marrow decreased significantly in both 
HRG1+/+ and HRG1-/- mice three days post-clodronate treatment (Fig. 3.15B), 
consistent with previous reports that in vivo depletion of macrophages by clodronate 
negatively impacts erythropoiesis190. Analyses of Ter-119+ subpopulations of 
erythroblasts in the bone marrow show a shift in maturation of erythroblast 
populations towards later stages after clodronate treatment compared to control (Fig. 
3.15C, 3.16A, B; populations V and IV). At days 7 and 14 post-clodronate injection, 
the erythroblast subpopulations return to levels similar to control mice (Fig. 3.15C, 
3.16A, C, D) In the spleen, where extramedullary erythropoiesis can occur, total 
erythroid cells increased significantly after clodronate treatment before returning to 
normal levels 7 days post-injection (Fig. 3.17A), indicative of stress erythropoiesis 
caused by clodronate190. Similar to the bone marrow, splenic erythroblasts showed a 
decrease in immature subpopulations (Fig. 3.17B, populations III+II+I) but with no 
corresponding increase in mature subpopulations (Fig. 3.17B, populations V+IV). 
Splenic erythroblast subpopulations resumed to control levels 14 days post-clodronate 






Figure 3.13 Clodronate-liposome injection depletes RES macrophages in vivo 
(A) Spleen, (B) liver and (C) bone marrow F4/80 immunohistochemistry analysis of 
paraffin-embedded tissue sections Control animals were injected with control-
liposomes, day 3 and 7 indicates mice which were injected with clodronate-






(D) Flow cytometry quantification of F4/80hiTreml4+ RPMs in control and 







Figure 3.14 Hemozoin remains in interstitial spaces of HRG1-/- RES tissues in 
absence of macrophages 
High magnification images of HRG1-/- spleen, liver and bone marrow on Day 3 post-
clodronate. Tissue sections were lightly stained with hematoxylin. Yellow arrows 







Figure 3.15 Clodronate treatment causes changes in bone marrow erythropoiesis 
(A) Hematocrits of mice treated with control or liposome liposomes. n=6-14.  
(B) Quantification of total Ter-119+ cells in bone marrows of mice treated with 
control or liposome liposomes. n=2-6. The %single cells* on the y-axis denote single 
cells that are negative for CD4/8/41, B220 and Gr-1.   
(C) Quantification of subpopulations of Ter-119+ cells represented as a percentage of 
total Ter-119+ cells in the bone marrow of mice treated with control or liposome 








Figure 3.16 Clodronate treatment enhances maturation of erythroblasts in bone 
marrow 
Quantification of subpopulations of Ter-119+ cells represented as a percentage of 
total Ter-119+ cells in the bone marrow. n=2-6.  
(A) Control liposome-treated mice. 
(B-D) Clodronate liposome-treated mice on days 3, 7 and 14 post-treatment. At least 







Figure 3.17 Clodronate treatment leads to splenic stress erythropoiesis 
(A) Quantification of total Ter-119+ cells in spleens of mice treated with control or 
liposome liposomes. n=2-6. The %single cells* on the y-axis denote single cells that 
are negative for CD4/8/41, B220 and Gr-1.  
(B) Quantification of subpopulations of Ter-119+ cells represented as a percentage of 
total Ter-119+ cells in the spleens of mice treated with control or liposome liposomes. 







There was no gross difference in the appearances of spleens or livers of 
HRG1+/+ mice after clodronate treatment (Fig. 3.18A-D) but HRG1-/- livers appeared 
to be darker in color after cloronate treatment (Fig. 3.18B, D). Non-hemozoin heme 
levels, which were initially higher in HRG1-/- spleens, decreased significantly post-
clodronate treatment (Fig. 3.19A), with a concomitant increase in the liver post-
clodronate(Fig. 3.19B), but no significant changes in the kidneys (Fig. 3.19A-C). 
Surprisingly, hemozoin levels in HRG1-/- spleens decreased significantly after 
clodronate treatment (Fig. 3.20A), while hemozoin levels in HRG1-/- livers increased 
significantly (Fig. 3.20B); hemozoin was not detected in HRG1-/- kidney or 







Figure 3.18 HRG1-/- livers show darkening post-clodronate treatment 
Images of (A) spleens and (B) livers from control and clodronate liposomes-treated 
mice on day 3 post-treatment. 
Images of (C) spleens and (D) livers from control and clodronate liposomes-treated 






Figure 3.19 Non-hemozoin heme levels decrease in spleens but increase in livers 
of HRG1-/- mice after clodronate treatment 
(A) Spleen, (B) liver and (C) kidney non-hemozoin heme levels of control and 






Figure 3.20 Hemozoin levels decrease in spleens but increase in livers of HRG1-/- 
mice after clodronate treatment 
(A) Spleen and (B) liver hemozoin levels in control and clodronate treated HRG1-/- 






While histochemical staining by Perls’ Prussian blue did not show differences 
in iron deposits, HRG1-/- liver from mice treated with clodronate appear to contain 
more hemozoin deposits in the liver, in spaces between hepatocytes (Fig. 3.21), 
which corresponds to the quantification by extraction and spectrophotometric 







Figure 3.21 Hemozoin accumulates in interstitial spaces of clodronate-treated 
HRG1-/- livers 
Histochemical staining of HRG1-/- livers by Perls’ Prussian blue of control and 
clodronate treated mice. Images shown are representative of at least 2 mice per group. 







During erythrophagocytosis in macrophages, heme transporter HRG1 and iron 
transporter NRAMP1 both localize to the erythrophagosomal membrane, transporting 
heme and iron into the cytosol for recycling107,109. The NRAMP1-/- mouse displays 
modest changes with regards to erythrocyte iron recycling108, indicating that the 
major source of recycled iron is derived from heme. Previously, in cellula studies 
using murine bone marrow-derived macrophages revealed that HRG1 transports 
heme out of the phagolysosome during erythrophagocytosis109. The prevailing model 
would predict that a complete loss of HRG1 would lead to ineffective heme-recycling 
and heme accumulation within phagolysosomes of macrophages. Combined with the 
known toxic properties of heme, cellular heme accumulation could potentially cause 
macrophage death, as seen in the HMOX1-deficient mouse137. We observed that 
HRG1-/- mice were indeed incapable of recycling heme-iron efficiently from ingested 
RBCs, resulting in heme accumulation in RES tissues. Tissue metal concentrations 
were also aberrant in HRG1-/- tissues, suggesting a dysregulation in systemic balance 
of metal concentrations. HRG1-/- macrophages showed heme sequestration within 
LAMP1+ compartments. However, unlike the complete loss of RES macrophages in 
HMOX1-deficient mice, HRG1-/- mice retained splenic RPMs, albeit at significantly 
lower levels as compared to HRG1+/+ mice. The sequestered heme was identified as 
an inert, crystalline form of heme, known as hemozoin. Consistent with the function 
of hemozoin formation in blood-feeding parasites, hemozoin formation in HRG1-/- 
macrophages appears to be a mechanism of heme tolerance, protecting RES 





clodronate administration released hemozoin into interstitial spaces of RES tissues 
but did not rescue anemia, suggesting that iron and heme from hemozoin is not 
bioavailable for erythropoiesis. In addition to ineffective heme recycling, HRG1-/- 
mice also showed ineffective bone marrow erythropoiesis concomitant with reduced 
hematocrits and splenic extramedullary erythropoiesis. These observations suggest 
that the cellular location of heme accumulation can dictate the cytotoxicity. We also 
showed the first incidence of mammalian hemozoin formed in vivo, suggesting that 
mammals have an additional form of heme detoxification mechanism - through 





Chapter 4 : Iron metabolism is aberrant in HRG1-deficient mice 
Summary 
Mice obtain their daily requirement of iron from both dietary and recycled 
sources. It has been shown that mice on an iron-rich diet can circumvent a block in 
heme-iron recycling by relying more on dietary iron for erythropoiesis172. To 
understand the implications that a defective heme-iron recycling pathway has on 
systemic iron metabolism, we placed HRG1-/- mice on a low-iron diet. We observe 
that under prolonged dietary iron limitation, HRG1-/- mice are unable to sustain 
erythropoiesis and become severely anemic. The stress erythropoiesis response is 
inefficient and the bone marrow erythropoiesis defect is enhanced under dietary iron 
limitation. HRG1-/- mice also retain tissue hemozoin under iron-deficiency and show 
aberrant regulation of iron metabolism genes. Under iron-deficiency anemia, HRG1-/- 
mice accumulate more hemozoin in the liver. Despite dysregulation in iron 
metabolism, HRG1-/- mice, surprisingly, do not display altered dietary iron uptake or 
distribution.  
Results 
HRG1-/- mice are susceptible to extreme anemia under prolonged dietary iron limitation 
The standard rodent diet fed to mice contains 380 ppm of iron, which is more 
than five times the amount of iron (25 to 100 ppm) required for normal growth and 
hematopoiesis of laboratory mice191. Given that the amount of recycled iron 
contributes to approximately 50% of the total daily iron needs of mice and the 





the relative contribution of recycled iron to the daily erythropoietic needs. HRG1-/- 
mice are inefficient in recycling heme-iron, but they do not show an overt defect in 
RBC production under basal conditions. To evaluate the impact of heme-iron 
recycling, we placed weaned mice on a diet containing 10 ppm iron and observed the 
effects of limiting dietary iron on erythropoiesis by monitoring hematocrit weekly. 
Over a period of six weeks post-weaning, we observed that both HRG1+/+ and HRG1-
/- mice showed a gradual increase in hematocrit, although HRG1-/- mice showed 
hematocrits that were significantly lower than HRG1+/+ mice (Fig. 4.1A). This 
indicates that the defect in heme-iron recycling only manifests into iron-deficiency 
anemia in HRG1-/- mice when dietary iron becomes limiting and body iron stores are 
lowered. 
To further understand changes in iron metabolism and response to iron-
deficiency in the HRG1-/- mice, we placed the mice on a low-iron diet (2 ppm Fe). 
Over a period of five weeks, both HRG1+/+ and HRG1-/- mice exhibited similarly-
reduced hematocrits, although HRG1-/- mice become anemic quicker than HRG1+/+ 
mice (Fig. 4.1B). However, over 20 weeks, anemic HRG1+/+ mice maintained their 
hematocrit while HRG1-/- mice showed a dramatic decline (Fig. 4.1C), eventually 






Figure 4.1 HRG1-/- mice rely on dietary iron to sustain erythropoietic needs 
Hematocrits of HRG1+/+ and HRG1-/- mice placed on a moderate (10 ppm) (A), 
standard or low (2 ppm) iron diet over 5 (B) to 20 (C) weeks. Mice were placed on 
respective diets supplemented with deionized water starting at 21 days of age (week 







Figure 4.2 A low-iron diet leads to mortality in the absence of heme-iron 
recycling 
Survival curve of HRG1+/+ and HRG1-/- mice placed on a low iron (2 ppm) diet over 
20 weeks. The experiment was terminated for HRG1-/- mice when less than 50% of 
HRG1-/- mice were surviving (16 weeks), while HRG1+/+ mice were monitored up to 






Iron-deficiency-induced stress erythropoiesis response is defective in HRG1-/- mice 
A major hallmark of iron-deficiency anemia in mice is splenomegaly, as mice 
are able to compensate for reduced bone marrow erythropoiesis by inducing stress 
erythropoiesis in the spleen65. After five weeks of being fed a low-iron diet (2 ppm 
Fe), HRG1+/+ and HRG1-/- mice were both anemic with similar hematocrits (Fig. 
4.1B). HRG1+/+ mice showed ~130% increase in splenic weights (or % 
splenomegaly) when compared to mice on a standard diet, indicating splenic stress 
erythropoiesis (Fig. 4.3A). However, the % splenomegaly experienced by HRG1-/- 
mice was significantly lower (~45%) (Fig. 4.3A). No significant differences in 
weights were observed for other organs from mice maintained on a low-iron diet for 
five weeks (Fig. 4.3B).  Flow cytometry analysis of the splenic erythroid 
compartments revealed that the stress erythropoiesis response in iron-deficient HRG1-
/- mice was significantly attenuated compared to HRG1+/+ mice (Fig. 4.4A, B). 
HRG1-/- mice had significantly lower amounts of total Ter-119+ cells in the spleen 
and a concomitant attenuated increase in immature populations. There was also a 
corresponding block in erythroblast differentiation at an earlier stage (population I) in 
the bone marrows of iron-deficient HRG1-/- mice (Fig. 4.4C). Taken together, these 
differences suggest that HRG1-/- mice are unable to respond effectively to iron-
deficiency anemia and are more severely impacted by the low-iron diet despite 







Figure 4.3 HRG1-/- mice show attenuated splenomegaly in response to iron-
deficiency 
(A) %Splenomegaly of HRG1+/+ and HRG1-/- mice calculated by the percentage of 
increase in average wet weight of spleens between mice on low iron versus standard 
iron diets (n=9-15). (B) Wet weights of liver, kidneys, heart, brain and body weights 






Figure 4.4 HRG1-/- mice display attenuated stress erythropoietic response 
(A) Quantification of total Ter-119+ cells in iron-deficient mice spleens represented 
as a percentage of all single cells analyzed in the spleen. The %single cells* on the y-
axis denote single cells that are negative for CD4/8/41, B220 and Gr-1. (B) Ratio of 
2ppm splenic Ter-119+ population II+III cells to that of standard diet mice (n=8-12). 
(C) Quantification of subpopulations of Ter-119+ cells in iron-deficient mice bone 
marrows represented as a percentage of total Ter-119+ cells in the bone marrow (n=7-
8). At least 100,000 single cells were analyzed per sample. Where applicable, each 





Although circulating serum iron, TIBC, transferrin, hepcidin, EPO, hemopexin, and 
haptoglobin did not show significant differences between iron-deficient HRG1+/+ and 
HRG1-/- mice, serum ferritin remained significantly elevated in HRG1-/- mice (Table 
4-1). Tissue iron and heme levels in RES organs were also significantly higher in 
iron-deficient HRG1-/- mice compared to HRG1+/+ mice (Fig. 4.5A, E). HRG1-/- iron-







Figure 4.5 Tissue metal and heme concentrations of iron-deficient HRG1+/+ and 
HRG1-/- mice 
Quantification of tissue iron (A), copper (B), manganese (C), zinc (D), and heme (E) 
by ICP-MS and UPLC, respectively in tissues of mice fed a standard diet (n=9-15). 





Table 4-1. Serum parameters of iron-deficient 10-week old HRG1+/+ and HRG1-/- 
mice 
 




Serum Iron (μg/dL) 66.32±13.62 65.63±17.09 8-10 
TIBC (μg/dL) 451.8±17.08 459±19.92 8-10 
Transferrin 
saturation (%) 
14.3±2.975 14.6±4.034 8-10 
Ferritin (ng/mL) 284.7±63.8a 492±63.77b 11-15 
Transferrin (g/L) 6.454±0.8177 6.794±0.941 11-15 
EPO (pg/mL) 3217±668.3 3908±1094 9-10 
Hepcidin (ng/mL) 34.72±1.025 33.55±0.9522 5-7 
Haptoglobin (mg/mL) 0.2259±0.1369 6.237±2.937 5-7 
Hemopexin (mg/mL) 1.169±0.1498 1.289±0.1988 4-9 
*2ppm diet indicates parameters from mice that were fed a low-iron diet for five 
weeks 






HRG1-/- mice show aberrant genetic regulation of iron metabolism genes 
To understand the molecular basis for the dampened response to iron-
deficiency in HRG1-/- mice, we analyzed the genetic profile of iron metabolism genes 
in the spleen, liver and kidney. A total of 90 genes reported to be involved in iron 
metabolism (collectively termed iron regulon) were assayed from HRG1+/+ and 
HRG1-/- mice, either on a standard (380 ppm) or low-iron (2ppm Fe for 5 weeks) 
rodent diet. The relative expression profiles are represented as heatmaps in Fig. 4.6 
(spleen), Fig. 4.7 (liver) and Fig. 4.8 (kidney). When comparing HRG1+/+ and HRG1-
/- mice on a standard diet, expression of three genes were significantly different in the 
spleens and livers. Conversely, the genetic profile of the iron regulon drastically 
changed under a low-iron diet, resulting in 30% of genes that were significantly 
dysregulated in the spleens of HRG1-/- mice compared to HRG1+/+ mice (Fig. 4.6). In 
the liver, 6% of the 90 genes were differently expressed between iron-deficient 






Figure 4.6 Heatmap of iron metabolism gene expression in spleen 
Gene expression heat map of 90 iron metabolism genes in spleens from mice on 
standard or low iron (2ppm) diet. Pearson correlation was used for comparison; 






Figure 4.7 Heatmap of iron metabolism gene expression in liver 
Gene expression heat map of 90 iron metabolism genes in spleens from mice on 
standard or low iron (2ppm) diet. Pearson correlation was used for comparison; 











Figure 4.8 Heatmap of iron metabolism gene expression in kidney 
Gene expression heat map of 90 iron metabolism genes in spleens from mice on 
standard or low iron (2ppm) diet. Pearson correlation was used for comparison; 






Strikingly, splenic HAMP was significantly upregulated in iron-deficient 
HRG1-/- mice and of all 36 genes that were significantly upregulated in HRG1-/- 
spleens at least 10 genes are known to be involved in regulation of HAMP (Fig. 4.9). 
One significantly upregulated gene, bone morphogenic protein 6 (BMP6), is a key 
inducer of hepicidin41 as BMP6-null animals display reduced liver hepcidin 
expression and iron overload40. Other genes involved in the BMP6-hepcidin 
regulatory pathway that were significantly upregulated include TMPRSS6192 and 
HFE193,194. Hepcidin may also be induced independently by IL-6195, Il-22196 and 
NOX4197, which were all significantly upregulated in HRG1-/- spleens. qPCR analysis 
of iron-deficient HRG1-/- spleens also revealed significant differences in the 
inflammatory status of these animals. Expression of toll-like receptor TLR3 involved 
in the signaling leading to pro-inflammatory cytokine IL-6150 production was 
significantly higher in HRG1-/- spleens. SAA1 and HMOX1, two common 
inflammatory status markers, were also significantly upregulated. SAA1 is an acute-
phase protein typically used as a sensitive marker of inflammation in mice198 and 
HMOX1 is usually produced by cells undergoing stress as a mediator to promote 
inflammatory modulation199,200. Taken together, there appears to be a general trend of 
inflammation in HRG1-/- spleens under iron-deficiency. However, despite the 
significant difference between HRG+/+ and HRG1-/- spleens, only few genes were 
significantly disrupted in the livers (Fig. 4.10) and kidneys (Fig. 4.11). This suggests 
that the major differences between HRG+/+ and HRG1-/- mice originate from the 
spleen and its inability to cope with iron-deficiency for stress erythropoiesis 





erythropoiesis as well as for recycling, although the liver has been shown to undergo 







Figure 4.9 Significant dysregulation of genes in HRG1-/- spleens 
(A-B) Gene expression by qPCR of iron metabolism genes in the spleens of HRG+/+ 
and HRG1-/- mice on indicated diets (n=9 mice per group). Gene expression values 







Figure 4.10 Significant dysregulation of genes in HRG1-/- livers 
Gene expression by qPCR of iron metabolism genes in the livers of HRG+/+ and 
HRG1-/- mice on indicated diets (n=9 mice per group). Gene expression values were 







Figure 4.11 Significant dysregulation of genes in HRG1-/- kidneys 
Gene expression by qPCR of iron metabolism genes in the kidneys of HRG+/+ and 
HRG1-/- mice on indicated diets (n=3 mice per group). Gene expression values were 






HRG1-/- mice accumulate hemozoin despite severe iron-deficiency anemia 
Liver macrophages, known as Kupffer cells, have also been shown to be 
involved in iron-recycling by erythrophagocytosis202. Hence, we observed 
accumulation of hemozoin in liver macrophages. Quantification of non-hemozoin 
heme (Fig. 4.12A, C, E) and hemozoin (Fig. 4.12B, D, F) appears to suggest that 
there is a negative correlation of tissue heme with hematocrit values in the spleen and 
liver (Fig. 4.12A-D) but not bone marrow hemozoin (Fig. 4.12E, F). The increase in 
liver hemozoin could be a consequence of increased erythrophagocytosis of senescent 
circulating erythrocytes by Kupffer cells as a compensatory pathway. This hypothesis 
would correlate with an increased turnover of circulating erythrocytes and can be 
evidenced by a decreased erythrocyte lifespan. However, in vivo biotin-labelling of 
circulating erythrocytes did not show differences in RBC life span in HRG1-/- mice 









Figure 4.12 Tissue heme and hemozoin quantifications from HRG1-/- mice of 
varying hematocrits 
Quantifications of (A, C, E) non-hemozoin heme and (B, D, F) hemozoin in the (A, 
B) spleens, (C, D) livers, and (E, F) bone marrows of HRG1-/- mice plotted against 
the hematocrit of each mouse. One point represents a single mouse. For bone marrow, 






Figure 4.13 Circulating erythrocyte lifespan in HRG+/+ and HRG1-/- mice 
Percentage of biotinylated erythrocytes in the circulations of HRG+/+ and HRG1-/-
mice on a (A) standard or (B) low-iron (2ppm) diet. Biotin injections were made on 






HRG1-/- mice do not display altered dietary iron uptake or distribution 
While HRG1-/- mice experience ineffective erythropoiesis in the bone marrow 
and extramedullary erythropoiesis in the spleen, they do not exhibit iron-deficiency 
symptoms under standard conditions. Their serum hepcidin and EPO are not 
significantly different from HRG1+/+ mice (Table 3-2). Using radiolabeled 59Fe, we 
were able to measure any differences in dietary iron uptake and distribution by oral 
gavage. Under both basal and iron-deficient conditions, HRG1+/+ and HRG1-/- mice 
did not show differences in total intestinal iron absorption or distribution to various 
tissues (Fig. 4.14A-D), although intestinal absorption was enhanced under iron-
deficiency (Fig. 4.14E). Likewise, when 59Fe was administered intravenously (IV) 
with 5 µg of FeSO4 to measure transferrin-bound iron (TBI) uptake, tissue iron 
distribution were similar between HRG1+/+ and HRG1-/- mice (Fig. 4.15A, B). 
However, when 59Fe was administered IV with excess FeSO4 (70 µg), which saturates 
circulating transferrin, to measure non-transferrin-bound iron (NTBI) uptake, the 59Fe 
distribution pattern to various tissues differed between HRG1+/+ and HRG1-/- mice 
(Fig. 4.15C, D). We observed that significantly more 59Fe-NTBI was distributed to 






Figure 4.14 Intestinal iron absorption and distribution is not significantly altered 
in the absence of HRG1 
Distribution of dietary 59Fe in the spleen, liver, kidney, heart, brain, pancreas, bone 
marrow, blood, gastrointestinal (GI) tract, and carcass of mice on a (A, B) standard or 





genotype; (C, D) n=3 per genotype. (E) Percentage dietary iron absorption calculated 








Figure 4.15 Serum iron distribution is altered in HRG1-/- mice 
Distribution of intravenously (IV) administered 59Fe in the spleen, liver, kidney, 
heart, brain, pancreas, bone marrow, blood, gastrointestinal (GI) tract, and carcass of 
mice on a standard diet through (A, B) transferrin-bound iron or (C, D) non-
transferrin-bound iron. (A, B) n=3 per genotype; (C, D) n=6 per genotype. Counts 








Since daily iron requirement is composed of both dietary and recycled iron, 
we hypothesized that the impacts of ineffective heme-iron recycling in HRG1-/- mice 
were compensated by greater absorption of dietary iron. Through 59Fe metabolic 
uptake studies, we observed no differences in dietary iron absorption in HRG1+/+ and 
HRG1-/- mice. To further understand the potential severity of ineffective heme-iron 
recycling by HRG1, we placed HRG1+/+ and HRG1-/- mice on a moderate (10 ppm) 
and low-iron (2 ppm) diet. Both diets led to HRG1-/- mice having significantly 
reduced hematocrits and when placed on the low-iron diet for long-term, HRG1-/- 
mice were unable to sustain erythropoiesis, resulting in death. Analyses of iron-
deficient mice with similar hematocrits at week 5 revealed that HRG1-/- mice were 
unable to induce stress erythropoiesis effectively. Gene expression analyses suggested 
that the pathways that allow for an iron-deficiency stress response were aberrantly 
regulated in HRG1-/- mice, as these mice continued to experience tissue iron overload 
through hemozoin accumulation. It therefore appears that in the absence of HRG1, 
there is disconnect between the tissue iron status and systemic iron status, resulting in 
a contradictory genetic response to iron-deficiency. HRG1-/- mice also appeared to 
accumulate more hemozoin during iron-deficiency, despite having no observable 
differences in erythrocyte lifespan.  Unexpectedly, HRG1-/- mice on a standard diet 
showed enhanced partitioning of NTBI but not TBI to the spleen. As there is stress 
erythropoiesis occurring in the spleens of HRG1-/- mice under normal conditions 
showing an increase in immature erythroid population of cells, this could suggest that 





erythropoiesis. NTBI is a chelatable pool of iron in the plasma that believed to be a 
major contributor to tissue iron loading and related pathologies in iron overload 
disorders8,203. Studies have shown that the main organs of NTBI clearance are the 
liver, followed by the pancreas and kidney. NTBI uptake is mediated by NTBI 
transporters including ZIP14, ZIP8, T-type calcium channels, DMT1, and 
TRPC610,204. While there is evidence of a ZIP14-independent NTBI uptake by the 






Chapter 5 :  Role of HRG1 in intestinal heme transport 
Summary 
Iron-deficiency affects more than two billion people in the world and 
manifests as anemia205. It is one of the most common diet-related disorder and can be 
remedied in most cases by iron supplementation206. Heme is a major dietary source of 
iron as it is more readily absorbed than inorganic iron in the human intestine11,12. As 
mentioned previously, the intestinal heme transporter remains elusive. While a mouse 
model lacking intestinal HRG1 appears to be a suitable model, studies in mice reveal 
no significant dietary heme uptake, indicating that mice may be an inappropriate 
model to evaluate intestinal heme absorption207. Some potential caveats are strain 
differences in mice as most genetic mutations are in the C57BL/6J background which 
contains a genetic variant in MON1a, resulting in a defect in endosomal protein 
trafficking208, and NRAMP1, the phagosomal divalent metal transporter; and that 
heme is imported by murine enterocytes but not exported from the basolateral 
surface, a concept recently underscored by the observation that HMOX1 expression is 
upregulated when mice are fed heme-rich diet but they remain anemic207. Here, we 
present preliminary results for two alternate model systems - Caco-2 cells, a human 
intestinal cell line, and piglets to study intestinal heme absorption.  Using Caco-2 
cells, we show that HRG1 expression is regulated by heme and localizes to subapical 
or apical compartments in polarized cells.  HRG1-knockout Caco-2 cells, generated 
using CRISPR-Cas9, are unable to upregulate HMOX1 induction upon heme 
exposure. Furthermore, we show that heme-supplemented diet is unable to rescue 





reverse anemia. Together, these results suggest that there is a mechanism for 







Generation of HRG1-knockout Caco-2 cells 
As observed in macrophages, HRG1 expression is upregulated by exogenous 
heme in the colonic adenocarcinoma cell line Caco-2 TC7 clone (Fig. 5.1A) but not 
in the Bbe or HTB-37 clones (Fig. 5.1B, C). Hence, we decided to focus on the TC7 
clone to generate HRG1-knockout cells by CRISPR-Cas9. Using guide RNAs 
targeted to exon 1 (E1), exon 2 (E2) and exon 3 (E3) of SLC48A1 (encoding HRG1) 
(Fig. 5.2A), we obtained four clones that showed no detectable HRG1 protein (Fig. 
5.2B), and DNA sequencing revealed the precise genetic lesion in SLC48A1 within 
each clone (Table 5-1, APPENDIX X). Subsequent characterization of HRG1-
knockout Caco-2 cells was conducted using the E1 and E1+E3 #1 clones. When 
wildtype and HRG1-knockout Caco-2 cells transduced with lentiviral HRG1-GFP 
were polarized, HRG1 intracellular localization changed from vesicular membranes 






Figure 5.1 HRG1 expression changes to heme treatment in different Caco-2 cell 
clones 
HRG1 expression in (A) TC7, (B) Bbe and (C) HTB-37 Caco-2 cells via 
immunoblotting.Cells were treated with basal, heme depleted (HD), HD with succinyl 
acetone (SA), and different concentrations of heme with deferroxamine (DFO) for 24 






Figure 5.2 Generation of HRG1-knockout Caco-2 cells 
(A) Gene loci of HRG1 indicating the CRISPR target sites in exon 1, 2 and 3.  






Figure 5.3 HRG1 localization in polarized and unpolarized wildtype and HRG1-
knockout Caco-2 cells 
(A, B) Confocal images of polarized wildtype Caco-2 cells transduced with HRG1-
GFP lentivirus and with immunofluorescence of HRG1 or E-cadherin. 
(C) Confocal image of unpolarized HRG1-knockout Caco-2 cells transduced with 





(D) Confocal image of polarized HRG1-knockout Caco-2 cells transduced with 







Table 5-1. Summary of HRG1-knockout Caco-2 clones 
Clone Genotype Protein 
C1 (Control) WT Present 
C2 (Control) WT Present 
E1 1 nucleotide indel Absent 
E1+E2 Deletion (E1 to E2) Absent 
E1+E3 #1 Deletion (E1 to E3) Absent 








HRG1-/- Caco-2 cells show lower induction of HMOX1 by heme 
In non-polarized cells, HMOX1 is reduced in the absence of HRG1 when 
compared to wildtype cells (Figure 5.4A, B). A similar result was observed in 
polarized cells when heme was added to the basolateral side of the growth medium 
(Fig. 5.5A, B).  Although this is surprising, this result is consistent with previous 








Figure 5.4 HMOX1 induction by heme treatment is suppressed in unpolarized 
HRG1-knockout Caco-2 cells 
(A) HMOX1 gene expression (normalized to housekeeping gene actin) by qPCR  
(B) HMOX1 protein expression by immunoblotting in wildtype (WT), control-
pooled(CP), E1 HRG1-knockout and E1+E3 HRG1-knockout unpolarized Caco-2 
cells treated with heme for 24 hours. CP cells were cells that were transfected with 
Cas9 but no guideRNA; i.e. they retain wildtype levels of HRG1 protein and no 







Figure 5.5 HMOX1 gene expression induction by heme is suppressed in polarized 
HRG1-knockout  Caco-2 cells 
(A, B) HMOX1 gene expression by qPCR in wildtype (WT), control-pooled(CP), E1 
HRG1-knockout and E1+E3 HRG1-knockout polarized Caco-2 cells treated with 






Pigs express HRG1 throughout intestinal tract 
Pigs appear to be a good model to study dietary heme absorption for various 
reasons. Firstly, studies have shown that pigs absorb heme via a specific 
mechanism210. The gastrointestinal (GI) tract of pigs also most closely resembles that 
of humans as compared to other non-primate models211. More importantly, nursing 
pigs reared in confinement suffer from iron-deficiency anemia. Piglets are born with a 
total body iron concentration of about 20 ppm, but as the sow’s milk is extremely low 
in iron (3 ppm), body iron stores cannot sustain the growth needs of piglets212. By 
three-weeks of age, piglets typically experience a growth spurt, quadrupling their 
birth weight. The anemia of piglets therefore provides a natural biomarker of dietary 
heme-iron absorption and utilization. Finally, the knowledge that pigs express HRG1 
throughout their GI tract was pivotal in choosing this animal model213. 
Hematocrits of iron-deficient pigs are partially rescued by hemoglobin-containing diet 
To observe the effects of a purified hemin-supplemented diet on iron-deficient 
piglets, we conducted a study with 21-day old iron-deficient piglets that were fed 
either an iron-deficient diet, hemin-supplemented diet, or an iron-supplemented diet. 
From our first study with 21-day old piglets, over a four-week period, a diet 
containing purified hemin was unable to rescue iron-deficiency anemia in contrast to 
iron-sulfate (Fig. 5.6A, B). Hemoglobin and hematocrit were used as measures of 
anemia. However, when the hemin-fed anemic piglets were switched to a porcine 
RBC-supplemented diet, anemia was rescued within two weeks (Fig. 5.6C, D). (The 
hematological parameters were collected by Ms. Elda Kwong in the Hamza Lab).  By 





was contained in hemin. Subsequent analyses of HRG1 protein expression in pig 
intestinal tissues did not show obvious patterns of regulation by diet, possibly due to 
the switching of diets after four-weeks, even though HRG1 was found to be expressed 
in pig spleen, liver and throughout the intestinal tract (Fig. 5.7).  Furthermore, 
immunolocalization studies in duodenal enterocytes of piglets have shown that HRG1 
localization changed to mostly apical membranes in response to hemoglobin-enriched 
diet213, raising the possibility that changes in HRG1 protein localization may be more 







Figure 5.6 Dietary hemin does not rescue iron-deficiency anemia in pigs 
(A, B) Hematocrit and hemoglobin levels in 21-day old piglets that were fed an iron-
deficient (-Fe), iron-sufficient (+Fe) or hemin-supplemented (heme) diet. n=5 per 
group. At the end of 4 weeks, the (n=3) iron-deficient pigs were transferred to a RBC-
supplemented diet. 
(C, D) Hematocrit and hemoglobin levels in pigs fed with RBC-supplemented diets 
over 2 weeks. Statistical significance represent differences in treatment groups versus 







Figure 5.7 Expression of HRG1 in different piglet tissues corresponding to diets 
fed 
Immunoblots of HRG1 in crude membrane preparations from spleens, liver, 
duodenum, jejunum, ileum and colon of piglets fed different diets. Fe A indicates 
piglets that were fed an iron-deficient diet and sacrificed at week 4, while Fe B 
represents piglets that were sacrificed at the end of the 6 week study. Ponceau 
stainings of each immunoblotting membrane can be found in APPENDIX XI. 
Discussion 
Multiple reports have alluded to a potential “receptor-mediated” mechanism 
for intestinal heme absorption in mammals15. However, the laboratory mouse, which 
is highly genetically tractable, has been proven to be unsuitable for the investigation 





iron207. Our attempts to study the role of HRG1 as an intestinal heme transporter 
utilizing human intestinal cell lines and piglets as a whole-animal model show 
promising preliminary results. Consistent with the subcellular locations of the 
duodenal iron importer DMT1214, HRG1 was observed to localize to the apical side of 
polarized Caco-2 cells, which suggests a function for HRG1 and heme transport from 
the lumen via the apical surface of intestinal epithelial cells. Although HRG1-
knockout Caco-2 cells also showed attenuated induction of HMOX1 with hemin 
treatments, the hemin application was from the basolateral surface.  This is 
unexpected as heme uptake should occur from the apical side facing the lumen.  
Potential explanations for this result is the use of hemin instead of a dietary-form of 
heme or that HMOX1 induction is dictated by systemic/circulatory levels of heme and 
that in the absence of HRG1, HMOX1 function is attenuated.  Therefore, further 
studies using bioavailable forms of heme, such as hemoglobin or heme complexed to 
smaller peptides, has to be conducted with polarized HRG1-knockout Caco-2 cells to 
evaluate the impact of HRG1-deficiency. Fluorescent heme analogs such as zinc 
mesoporphyrin may also be applied to the apical surface of polarized wildtype and 
HRG1-knockout Caco-2 cells and imaged using confocal microscopy to observe 
differences in intracellular heme absorption. Iron-deficient weanling piglets appeared 
to be a suitable model for dietary heme absorption studies and it is concluded that 
dietary heme absorption requires a form of bioavailable heme such as hemoglobin 
found in RBCs even though intestinal epithelial HRG1 steady-state abundance did not 
change in response to diets or anemia. Future studies are required to elucidate the 





Chapter 6 :  Conclusions and future directions 
Conclusions 
HRG1 was first identified in the heme auxotroph Caenorhabditis elegans 215 and 
later shown to play a role in mammalian heme transport in bone marrow-derived 
macrophages during erythrophagocytosis. HRG1 has also been implicated in 
erythropoiesis and heme-iron recycling in zebrafish174. The goal of this project was to 
understand the physiological impact(s) of HRG1 loss in a mammalian in vivo model 
and to investigate if HRG1 plays a role in intestinal heme transport. The major 
findings of this project are summarized below: 
1) Loss of HRG1 in mice results in systemic heme-iron overload, particularly in 
reticuloendothelial tissues (spleen, liver, bone marrow). Using differential 
extraction of heme, ICP-MS and UPLC, we observed tissue iron accumulation 
in the form of heme. Corresponding to heme-iron overload, serum ferritin 
levels are also elevated in HRG1-/- mice.  
2) HRG1-deficiency in mice results in ineffective heme-iron recycling by splenic 
and liver erythrophagocytic macrophages. In vivo recycling of 59Fe-labelled 
RBCs show increased retention of 59Fe in the form of heme and an insoluble 
heme pigment in HRG1-/- spleens and livers, indicating a defect in heme 
transport in the recycling process. 
3) Sequestered heme from phagocytosed RBCs accumulates in the form of 
hemozoin within lysosomes of HRG1-/- macrophages. Hemozoin, an inert 
crystalline heme molecule, localizes within enlarged LAMP1+ vesicles in 





4) In vivo macrophage depletion by inducing apoptosis with clodronate releases 
hemozoin, which accumulates within interstitial spaces in the liver. Released 
hemozoin does not translocate to the kidney but is instead released from the 
spleen and accumulates in the liver. 
5) HRG1-/- mice contain fewer splenic red pulp macrophages and greater 
numbers of maturating monocytes. The decrease in red pulp macrophages 
could be due to heme toxicity as HRG1-/- mice contain significantly more 
heme in the spleen. 
6) Ineffective erythroblast maturation from basophilic to polychromatic stage in 
HRG1-/- mice results in reduced RBC production and significantly lower 
hematocrits. While other hematological parameters of the HRG1-/- mice are 
normal, the reduction in RBC production suggests a role for HRG1 in 
erythropoiesis.  
7) HRG1-/- mice experience extramedullary erythropoiesis in the spleen, 
corresponding to ineffective bone marrow erythropoiesis. This is accompanied 
by significantly higher serum transferrin levels, which are typically indicative 
of systemic iron-deficiency. 
8) Under prolonged dietary iron limitation, HRG1-/- mice are unable to maintain 
erythropoiesis and experience severe iron-deficiency anemia. This is a 
consequence of restricted dietary iron compounded by a block in recycling of 
heme-iron due to HRG1-deficiency. In addition, HRG1-/- mice are unable to 
induce a splenic stress erythropoiesis response to iron-deficiency and suffer 





9) HRG1-deficiency results in an aberrant response to iron-deficiency. Spleen 
hepcidin, a potential regulator of systemic iron metabolism, was insufficiently 
suppressed in HRG1-/- mice during iron-deficiency. Moreover, 30% of the 90 
iron metabolism genes assessed was significantly different in HRG1-/- spleens 
with more than 10 genes that were involved in the hepcidin regulation 
pathway.  
10)  Despite tissue heme-iron overload and signs of iron-deficiency, HRG1-/- mice 
have similar overall tissue distribution of dietary iron and TBI. However, non-
transferrin bound-iron (NTBI) was observed to accumulate in HRG1-/- 
spleens, suggesting the preference of NTBI as a source of iron for 
extramedullary erythropoiesis. 
11)  HRG1 may also function as an intestinal heme transporter.  In polarized 
Caco-2 human intestinal cell lines, HRG1 localizes to the subapical region in 
vesicles. This is in contrast to the punctate vesicular localization of HRG1 in 
macrophages and non-polarized Caco-2 cells. It suggests that membrane 
trafficking of HRG1 is dictated by cell polarization, and that heme transport 
by HRG1 in macrophages after digestion of senescent RBCs may share 
common molecular mechanisms with heme transport by HRG1 in enterocytes 
after digestion of dietary hemoproteins.   
12)  Iron-deficiency anemia is rescued by hemoglobin-supplemented diet in 
piglets but not by purified hemin. These results indicate that there exists a 
mechanism for intestinal heme-absorption through hemoglobin and the 






Systemic consequences of hemozoin accumulation 
Superficially, the accumulation of hemozoin in HRG1-/- mice appears to have 
no physiological impacts. However, several studies have shown that hemozoin from 
Plasmodium or β-hematin causes inflammatory responses187.  Therefore, it is possible 
that hemozoin in HRG1-/- mice are causing systemic inflammatory responses that 
have not been analyzed. To address this, we could measure the levels of inflammatory 
cytokines in the serum or lymph nodes. It is possible that HRG1-/- mice have adapted 
to hemozoin accumulation and needed to be challenged.  We could accomplish this 
by infecting them with parasites or bacteria and study the efficacy of immune 
responses to pathogens in the absence of HRG1 and presence of hemozoin.  
Mechanism of mammalian hemozoin formation 
As this is the first instance of mammalian hemozoin formation, whether the 
formation is an active enzymatic process or a chemical process is not known. To gain 
insights into possible target proteins that may be involved in hemozoin formation (if 
any), we could conduct protein analyses via mass spectrometry and compare 
HRG1+/+, HRG1-/- hemozoin-containing and HRG1-/- non-hemozoin containing 
lysosomes extracted from the respective macrophages. Identifying differentially 
expressed proteins would provide a list of genes that we could genetically manipulate 
in vivo to determine whether hemozoin formation is altered in HRG1-/- mice. These 
analyses can be conducted concurrently with RNA-sequencing of the same samples to 





Lysosomal integrity in HRG1-/- macrophages 
We observed that HRG1-/- macrophages contain hemozoin-laden LAMP1+-
vesicles which are significantly larger than the previously reported sizes of 
lysosomes. With the enlargement of these membrane compartments, it is possible that 
the lysosomal membrane is compromised and prone to leakage or breakage, as 
reported in lysosomal storage diseases. It is also possible that HRG1, a lysosomal 
membrane protein, aids in maintaining membrane integrity. Hence, we could 
investigate the impacts of 1) loss of HRG1 and 2) hemozoin accumulation or the 
combination of both on lysosomal membrane integrity. Through in vitro studies 
involving either naïve BMDMs or mature hemozoin-laden macrophages, we can 
measure lysosomal leakage through pH sensitive probes or recruitment of lysosomal 
damage proteins known to repair lysosomes. This can be done in both unperturbed 
conditions or under erythrophagocytosis where reorganization of the membranes and 
cytoskeleton is involved. 
Oxidative status in response to HRG1-deficiency 
Our preliminary analyses suggest that there is more heme in the non-
hemozoin form in HRG1-/- tissues. We can confirm the location of this heme at the 
cellular level, by using heme-sensors1 that are targeted to various intracellular 
compartments in HRG1-deficient macrophages after EP. If it is indeed true that 
HRG1-/- cells are exposed to more labile heme, the impacts of this labile heme should 
be investigated. Heme and iron are both known to cause oxidative stress through 
reactive oxygen species. To investigate this, we can analyze the oxidative status of 





markers such as gluthathione disulfide (GSSG) and gluthathione (GSH) levels or 
Nrf2, a signaling molecule which can induce oxidative stress responses. These 
measurements can also be done using in vitro cultured bone marrow macrophages and 
treating them with opsonized RBCs, to determine whether macrophages are exposed 
to more oxidative stress during erythrophagocytosis and in the absence of HRG1. A 
similar approach could be performed with phagocytosis of purified mammalian 
hemozoin or intracellular pathogens such as mycobacterium tuberculosis. 
Role of HRG1 in erythropoiesis 
HRG1-/- mice show ineffective erythropoiesis with more immature 
erythroblasts at the basophilic stage than HRG1+/+ mice. From the mouse cell atlas216, 
HRG1 expression is found in both erythroblasts and macrophages within the bone 
marrow. This suggests a role for HRG1 not only in erythrophagocytic macrophages, 
but potentially nurse macrophages and erythroblasts for erythroblast maturation. To 
delineate the roles of HRG1 in erythropoiesis, we could utilize cell-specific ablation 
of HRG1 in mice. The first potential model would be a macrophage-specific HRG1-
deletion and the second is a RBC-specific HRG1-deletion. The combination of these 
two mouse models would be able to give us insights into the relative contribution of 
cell-specific HRG1 on the ineffective erythropoiesis we observe in our current model 
of HRG1-deficiency. In addition, we could conduct erythroblast maturation analyses 
in vitro by isolating either entire erythroblastic islands or hematopoietic stem cells 





Protein interactions of HRG1 for heme transport 
The current model for erythrophagocytosis follows the fate of heme as it is 
transported out of the phagolysosome by HRG1 into the cytosol where HMOX1 can 
catabolize heme to liberate iron. Since HMOX1 was not observed to localize to the 
phagolysosomal membrane107, the interacting proteins required for heme transport in 
this process is not known. To identify potential interactors of HRG1, which may act 
as a chaperone for heme, we can conduct an immunoprecipitation of HRG1 followed 
by mass spectrometry such as the Multidimensional Protein Identification 
Technology (MudPIT)217. This can be conducted using in vitro cultured macrophages 
before, during and after erythrophagocytosis. By comparing the three time-points, we 
will be able to identify proteins whose interactions with HRG1 are enhanced by 
erythrophagocytosis. By shRNA-knockdown of these potential interactors in vitro and 
observing if heme metabolism is altered, we can identify targets that are required for 
heme recycling post-erythrophagocytosis. 
Role of HRG1 in intestinal heme absorption 
While laboratory strains of mice may be an inappropriate animal model to 
study in vivo heme absorption, we can exploit HRG1-knockout Caco-2 cells to 
perform cell biological studies and heme-uptake assays with 59Fe-heme. In addition, 
we can utilize 3D cell culture of intestinal organoids derived from either human 
induced pluripotent stem cells (iPSCs) or duodenal crypt cells from piglets218. We can 
generate HRG1-knockout cells through CRISPR-Cas9, which provides a 3D intestinal 
model to study heme absorption. We can use these models to conduct heme uptake 





immunofluorescence using fluorescent heme analogs like zinc-mesoporphyrin 
(ZnMP). 
Significance 
As previously mentioned, most genetic ablations of proteins involved in the heme-
iron metabolism has proven to result in embryonic lethality thus far. Only 
approximately 10% of HMOX1-null animals survive and the surviving animals do not 
have reticuloendothelial macrophages in their spleen, liver, bone marrow, and 
develop iron-deficiency anemia in old age with kidney iron overload137. In vitro 
differentiated HMOX1-/- bone marrow macrophages die with erythrophagocytosis due 
to heme toxicity. Ferroportin-null mice are embryonic lethal due to developmental 
defects and selective inactivation of FPN in the embryo resulted in iron accumulation 
in macrophages, hepatocytes and enterocytes219.  FLVCR-null animals lack definitive 
erythropoiesis and die in utero, while neonatal deletion of FLVCR results in a 
development of macrocytic anemia and iron overload in macrophages18,93. Ferritin-
null mice are also lethal during embryonic development due to the lack of ferroxidase 
activity by the H subunit220.  Our studies described herein show that HRG1-deficiency 
is not embryonic lethal, but results in ineffective heme recycling by macrophages. 
This inability to transport heme out of the phagolysosome leads to the formation of 
hemozoin, which to our knowledge, is the first instance of mammalian hemozoin. 
This discovery highlights an important aspect of mammalian cells - that they do have 
a heme tolerance mechanism by polymerizing heme into inert hemozoin in the 
phagolysosome. The conditions of lysosomes also appear to be similar to the 





formation of hemozoin in the absence of HRG1 makes HRG1 a potential therapeutic 
target in hemolytic diseases in which the macrophages are overwhelmed with high 
levels of intracellular toxic heme.  Thus, selective inhibition of HRG1 during a 
hemolytic crisis, as in sickle cell disease, could be beneficial to overcome cellular 
cytotoxicity.   
Our nutritional studies in HRG1-/- mice combined with the genetic analysis of iron 
metabolism genes in the spleen, liver and kidney also highlights a few ideas: 
1) Tissue iron levels affect gene expression profiles which dictate the overall 
responses to systemic iron levels 
HRG1-/- iron-deficient mice were unable to suppress iron-regulated genes unlike 
HRG1+/+ mice. This inability to appropriately regulate iron metabolism genes 
corresponded to their inability to enhance splenic erythropoiesis to increase 
erythrocyte production under iron-deficient conditions. Therefore, HRG1-/- mice 
maintained on a low-iron diet were susceptible to severe iron-deficiency anemia 
which led to death. We postulate that the accumulation of heme-iron resulted in the 
misperception of systemic iron overload, corresponding to elevated serum ferritin in 
HRG1-/- mice. 
2) Recycled iron as a sole source of iron can sustain life in mice 
HRG1+/+ mice developed iron-deficiency anemia on an iron-limiting diet but 
continued to maintain their hematocrit up to 20-weeks with no lethality. These 
anemic animals appeared to be able to adapt to a systemic iron-deficient condition 






Finally, our combined preliminary results using Caco-2 cells and piglets suggest that 
1) There is an active mechanism for dietary heme absorption, and  
2) HRG1 localizes to the apical/sub-apical surface in polarized intestinal epithelial 







Chapter 7 Appendices 
APPENDIX I 








APPENDIX II. List of primers used for qPCR of Caco-2 cells 
Primer Sequence 
hActin forward GGCATGGGTCAGAAGGATT 
hActin reverse AGGTGTGGTGCCAGATTTTC 
hHO1 forward AGACGGCTTCAAGCTGGTGAT 
hHO1 reverse CCTTGTTGCGCTCAATCTCCT 
hHO2 forward GAAGGAAGGGACCAAGGAAG 









APPENDIX III. X-ray diffraction pattern of purified hemozoin from HRG1-/- 
mice 
Top: Powder x-ray diffraction of purified insoluble fraction from HRG1-/- spleens 
(red: measured data; dark blue: calculated pattern; light blue: background; green: 
structural plot). 







APPENDIX IV. Scanning electron microscopy (SEM) images of Plasmodium 







APPENDIX V. Transmission electron microscopy images of HRG1+/+ and HRG1-
/- isolated bone marrow and splenic macrophages 
Transmission electron microscopy (TEM) of F4/80+ bone marrow and splenic 
macrophages from HRG1+/+ and HRG1-/- mice. At least 3 cells were imaged per 








APPENDIX VI. Transmission electron microscopy images of HRG1+/+ and 
HRG1-/-  in vitro differentiated macrophages and isolated monocytes 
TEM of in vitro-differentiated bone marrow macrophages and isolated bone marrow 








APPENDIX VII. X-ray fluorescence microscopy of F4/80+ bone marrow 

















APPENDIX IX. ROI concentration within hemozoin-laden areas in HRG1-/- 
BMMs. 

































APPENDIX XII. Expression profile of 90 iron metabolism genes in spleen 
Spleen 










+/+ vs -/- 
Standard 
+/+ vs -/- 
2ppm 
1 Ncoa4 0.460228 0.45156 0.677581 0.654086 0.785908 0.910494 
2 Ankrd37 0.077148 0.06764 0.042022 0.078109 0.203337 0.082088 
3 Smad7 0.076842 0.086016 0.021828 0.046165 0.274171 0.11449 
4 Neo1 0.008445 0.00909 0.004881 0.012302 0.65851 0.001396 
5 Mfsd7b 0.04416 0.040798 0.021812 0.036406 0.446136 0.056827 
6 Steap3 0.009364 0.008803 0.043108 0.03235 0.683205 0.675788 
7 Alas2 0.015192 0.013973 0.137159 0.114733 0.606314 0.844622 
8 Steap2 0.007771 0.008065 0.003611 0.008499 0.860607 0.00879 
9 Pcbp2 1.44205 1.489302 1.396467 1.437742 0.673885 0.83502 
10 Slc39a8 0.008971 0.010366 0.034527 0.018045 0.338525 0.259762 
11 Slc39a14 0.023129 0.022927 0.007918 0.015392 0.938729 0.086934 
12 Hmox2 0.132777 0.122484 0.067796 0.112948 0.353423 0.074152 
13 Slc11a2 0.07238 0.071503 0.132895 0.097686 0.856884 0.317352 
14 Il12a 0.054078 0.047771 0.017265 0.040463 0.315652 0.100251 
15 Heph 0.007771 0.008065 0.003892 0.010382 0.860607 0.00032 
16 Fbxl5 0.424975 0.393218 0.183384 0.370833 0.223873 0.020012 
17 Slc38a1 0.245817 0.22301 0.103132 0.195156 0.23564 0.054551 
18 Cp 0.149606 0.123381 0.053151 0.130496 0.040584 0.050688 
19 Nox4 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
20 Trfr2 0.008191 0.008065 0.015932 0.011385 0.937299 0.431137 
21 Tlr7 0.070707 0.06133 0.027631 0.076642 0.329741 0.05663 
22 Alas1 0.051966 0.047865 0.034113 0.051883 0.41855 0.087581 
23 Aco1 0.034538 0.029939 0.027705 0.033004 0.104746 0.164952 
24 Bmp6 0.008986 0.009215 0.004589 0.013405 0.867165 0.00041 
25 Epo 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
26 Fech 0.073222 0.061787 0.355397 0.316257 0.257168 0.85321 
27 Fxn 0.039113 0.040464 0.082965 0.055555 0.666486 0.159952 
28 Ifnab 0.02035 0.013281 0.007811 0.017754 0.258808 0.110244 
29 Il1b 0.032794 0.0297 0.023154 0.03559 0.623479 0.262454 
30 Lcn2 0.008039 0.008065 0.020481 0.036683 0.987727 0.339753 
31 Smad4 0.666844 0.634719 0.224429 0.472095 0.528873 0.081848 
32 Trim27 0.44057 0.409639 0.400956 0.39193 0.363565 0.84778 
33 Saa1 0.007771 0.008431 0.003604 0.008499 0.686138 0.008779 





35 Epas1 0.118297 0.122453 0.063605 0.126695 0.715891 0.085056 
36 Fth1 8.27107 7.823645 12.10742 10.12592 0.550265 0.231022 
37 Ftl1 3.051175 3.167726 2.439446 3.152218 0.621149 0.09736 
38 Gast 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
39 Ggh 0.061242 0.069158 0.041502 0.062903 0.270486 0.142022 
40 Herc2 0.323256 0.301078 0.273275 0.268044 0.354969 0.869643 
41 Hfe 0.027479 0.023567 0.018634 0.036539 0.363139 0.037129 
42 Hif1a 0.144096 0.12521 0.06031 0.10897 0.081934 0.156598 
43 Hmox1 0.061712 0.052363 0.066466 0.150277 0.452103 0.057685 
44 Id1 0.038423 0.041967 0.024664 0.045018 0.662734 0.100576 
45 Ifna2 0.01001 0.009491 0.005368 0.012305 0.850758 0.041967 
46 Ifna4 0.007771 0.008065 0.003759 0.008499 0.860607 0.008373 
47 Ifnb1 0.008262 0.008599 0.003884 0.008853 0.852075 0.010902 
48 Il10 0.007771 0.008065 0.003604 0.008846 0.860607 0.004212 
49 Il1a 0.018561 0.019324 0.01921 0.024782 0.773414 0.344068 
50 Nos2 0.586098 0.501664 0.31465 0.559412 0.762478 0.182222 
51 Spic 0.075424 0.071478 0.066295 0.104985 0.57783 0.269443 
52 Stat3 0.354791 0.341432 0.142882 0.287183 0.595846 0.099515 
53 Tfrc 0.0931 0.099157 0.602722 0.2551 0.554229 0.225457 
54 Pcbp1 0.682598 0.465519 0.631387 0.73657 0.308162 0.202 
55 Eif2ak1 0.123477 0.111092 0.276118 0.17224 0.220474 0.209149 
56 Slc11a1 0.019358 0.017986 0.014885 0.028003 0.580363 0.092705 
57 Neu3 0.028821 0.027812 0.060246 0.053327 0.835653 0.667419 
58 Slc40a1 0.083922 0.095411 0.166625 0.28874 0.384726 0.179292 
59 Il22 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
60 Hp 0.007771 0.008065 0.007638 0.013376 0.860607 0.047671 
61 Hpx 0.007771 0.008065 0.003604 0.008595 0.860607 0.007156 
62 Pcbp4 0.009495 0.012202 0.004643 0.010652 0.020129 0.003501 
63 Pcbp3 0.012452 0.012558 0.006289 0.01225 0.961568 0.027975 
64 Ireb2 0.200697 0.205773 0.137189 0.161649 0.721662 0.372345 
65 Ndfip1 0.31997 0.296984 0.159203 0.292991 0.268846 0.069558 
66 Glrx3 0.303586 0.295483 0.199801 0.284397 0.756802 0.12322 
67 Cisd2 0.046779 0.041849 0.034236 0.03579 0.519249 0.70719 
68 Slc25a37 0.184587 0.180537 0.716806 0.481279 0.769777 0.500716 
69 Slc48a1 0.154751 0.122308 0.247154 0.231763 0.023006 0.795474 
70 Asb11 0.007771 0.008065 0.00373 0.008499 0.860607 0.011532 
71 Hfe2 0.007771 0.008065 0.003604 0.009815 0.860607 0.000626 
72 Steap1 0.007771 0.008065 0.003604 0.008639 0.860607 0.00791 
73 Tmprss6 0.007771 0.008065 0.003604 0.008561 0.860607 0.007936 
74 Cybrd1 0.010012 0.01606 0.005803 0.011169 0.240113 0.116958 





76 Tlr9 0.18901 0.175538 0.065271 0.162854 0.559203 0.091765 
77 Hamp 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
78 Steap4 0.009093 0.009466 0.005369 0.009517 0.844773 0.086015 
79 Aco2 0.281366 0.271247 0.275595 0.268562 0.587524 0.778817 
80 Tlr3 0.015441 0.015644 0.007944 0.018626 0.946068 0.027149 
81 Cisd1 0.068871 0.065689 0.064531 0.059389 0.651308 0.417664 
82 Slc25a38 0.007771 0.008065 0.004564 0.008499 0.860607 0.051437 
83 Slc25a28 0.090025 0.085501 0.051173 0.076466 0.605732 0.113797 
84 Nox1 0.007771 0.008065 0.003605 0.008499 0.860607 0.008795 
85 Fam132b 0.02599 0.026918 0.127975 0.10671 0.83357 0.76172 
86 Bola2 0.921033 0.942639 0.696702 0.956523 0.764892 0.068752 
87 Nox3 0.007771 0.008065 0.003604 0.008499 0.860607 0.008779 
88 Slc11a2 0.027327 0.036439 0.039777 0.03899 0.159956 0.950754 
89 Slc11a2 0.062631 0.060864 0.091422 0.059077 0.80646 0.126955 








APPENDIX XIII. Expression profile of 90 iron metabolism genes in liver 
Liver 










+/+ vs -/- 
Standard 
+/+ vs -/- 
2ppm 
1 Ncoa4 2.104806 2.054607 1.840099 1.519775 0.842456 0.010102 
2 Ankrd37 0.026956 0.029494 0.085682 0.074238 0.686342 0.526779 
3 Smad7 0.045746 0.060019 0.042773 0.045979 0.088687 0.718038 
4 Neo1 0.088618 0.085184 0.079316 0.084068 0.623462 0.697684 
5 Mfsd7b 0.033904 0.0287 0.034737 0.029811 0.278941 0.486382 
6 Steap3 0.282205 0.379398 0.259662 0.211577 0.086504 0.301235 
7 Alas2 0.738493 0.827988 0.578526 0.659839 0.479046 0.605066 
8 Steap2 0.049261 0.045718 0.079847 0.083476 0.590147 0.782351 
9 Pcbp2 2.472163 2.660609 2.80595 2.293929 0.551858 0.040291 
10 Slc39a8 0.47985 0.515413 0.442933 0.463886 0.568555 0.698327 
11 Slc39a14 1.113893 1.281578 1.196207 1.240187 0.243892 0.749833 
12 Hmox2 0.500969 0.557152 0.547028 0.518539 0.23307 0.525405 
13 Slc11a2 0.266538 0.245697 0.402017 0.37846 0.51679 0.585676 
14 Il12a 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
15 Heph 0.012257 0.012459 0.011403 0.010497 0.925382 0.65044 
16 Fbxl5 0.330613 0.292015 0.326683 0.318606 0.306851 0.83004 
17 Slc38a1 0.009863 0.009664 0.013854 0.012196 0.858419 0.58464 
18 Cp 11.18418 11.29099 9.244314 10.39812 0.91491 0.361235 
19 Nox4 0.301777 0.369597 0.31618 0.232075 0.092537 0.254908 
20 Trfr2 1.397556 1.488136 1.472023 1.308716 0.534117 0.257797 
21 Tlr7 0.011021 0.013092 0.021151 0.024298 0.357052 0.576796 
22 Alas1 2.448702 2.371844 3.160594 2.155087 0.937472 0.12928 
23 Aco1 1.474099 1.462684 1.302615 1.191635 0.954875 0.612794 
24 Bmp6 0.026047 0.031494 0.011476 0.009744 0.217314 0.512344 
25 Epo 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
26 Fech 1.327336 1.405528 1.272371 1.251952 0.658019 0.908706 
27 Fxn 0.358537 0.367927 0.352618 0.32621 0.776755 0.458308 
28 Ifnab 0.017581 0.026947 0.014468 0.019398 0.213494 0.506078 
29 Il1b 0.061586 0.069314 0.102627 0.061808 0.72544 0.139748 
30 Lcn2 0.267921 0.128132 0.29268 0.464611 0.267906 0.5562 
31 Smad4 0.772931 0.71437 0.779715 0.86016 0.512164 0.508856 
32 Trim27 0.488392 0.486109 0.474558 0.432887 0.954172 0.297162 
33 Saa1 4.429164 2.245883 2.858346 3.647674 0.406544 0.754409 





35 Epas1 1.147802 1.351177 1.687153 1.768037 0.217485 0.708785 
36 Fth1 46.97091 48.5549 49.69345 40.89033 0.792539 0.181332 
37 Ftl1 46.89152 42.25637 28.7884 32.36782 0.390758 0.393369 
38 Gast 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
39 Ggh 0.285346 0.29256 0.323914 0.260677 0.83938 0.059112 
40 Herc2 0.35564 0.382736 0.383258 0.344749 0.384618 0.262309 
41 Hfe 0.561019 0.530981 0.488806 0.465035 0.683101 0.5818 
42 Hif1a 0.246592 0.26424 0.241707 0.270835 0.50479 0.283897 
43 Hmox1 0.104365 0.1158 0.192946 0.141604 0.592594 0.151771 
44 Id1 0.060124 0.070904 0.070147 0.062814 0.265836 0.739887 
45 Ifna2 0.009547 0.018035 0.010855 0.011244 0.010002 0.899766 
46 Ifna4 0.006703 0.006711 0.006229 0.007456 0.994363 0.62851 
47 Ifnb1 0.00675 0.009052 0.007154 0.00677 0.081153 0.678612 
48 Il10 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
49 Il1a 0.085707 0.089735 0.081813 0.061604 0.788144 0.064725 
50 Nos2 0.304159 0.436781 0.207065 0.229652 0.412871 0.89302 
51 Spic 0.01849 0.015979 0.042308 0.041677 0.268166 0.957923 
52 Stat3 1.169194 1.134505 1.087231 1.269853 0.823213 0.14194 
53 Tfrc 0.238403 0.221555 0.775859 0.853378 0.672732 0.600141 
54 Pcbp1 1.997149 1.983349 1.84455 1.876354 0.952889 0.902948 
55 Eif2ak1 0.38162 0.400133 0.373302 0.38837 0.694657 0.742811 
56 Slc11a1 0.028851 0.026178 0.054541 0.055204 0.627299 0.944282 
57 Neu3 0.041021 0.032129 0.038816 0.043619 0.134109 0.576291 
58 Slc40a1 0.968484 0.996529 0.999023 1.065346 0.854911 0.766943 
59 Il22 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
60 Hp 35.0992 27.749 32.50427 39.64732 0.296094 0.440617 
61 Hpx 69.92164 56.03077 57.41014 71.38555 0.17532 0.210616 
62 Pcbp4 0.048157 0.06004 0.044817 0.050902 0.160598 0.454102 
63 Pcbp3 0.009664 0.010573 0.009489 0.010926 0.543752 0.312287 
64 Ireb2 0.827994 0.76695 0.717796 0.781823 0.51992 0.493991 
65 Ndfip1 2.190142 2.236745 2.057999 1.917441 0.866357 0.575084 
66 Glrx3 1.133977 1.141158 1.237516 1.032026 0.952871 0.141758 
67 Cisd2 0.09629 0.102094 0.107751 0.113297 0.725393 0.689943 
68 Slc25a37 0.207294 0.225136 0.194363 0.198761 0.563322 0.896901 
69 Slc48a1 0.510877 0.319351 0.438605 0.268671 0.004204 0.004492 
70 Asb11 0.006174 0.006742 0.012435 0.008084 0.628657 0.524463 
71 Hfe2 1.412205 1.495065 1.893776 1.434467 0.674471 0.083435 
72 Steap1 0.006195 0.008248 0.007112 0.007579 0.107006 0.600925 
73 Tmprss6 1.199311 1.215268 1.141207 1.143271 0.936316 0.992596 
74 Cybrd1 0.007649 0.015536 0.009117 0.012143 0.010447 0.37467 





76 Tlr9 0.006821 0.007646 0.007404 0.007786 0.441323 0.733958 
77 Hamp 9.515957 19.43472 0.006229 0.009745 0.192934 0.116914 
78 Steap4 0.984624 0.965356 0.826565 0.967361 0.942259 0.525285 
79 Aco2 1.86685 2.084105 2.463018 1.978878 0.308786 0.316985 
80 Tlr3 0.03356 0.038133 0.048575 0.037533 0.526121 0.075002 
81 Cisd1 1.835598 2.215811 2.51588 1.820311 0.236467 0.059429 
82 Slc25a38 0.023206 0.038059 0.026684 0.031214 0.070787 0.727451 
83 Slc25a28 0.122955 0.14652 0.103535 0.112261 0.224229 0.46567 
84 Nox1 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
85 Fam132b 0.022474 0.025306 0.026509 0.023461 0.386068 0.348758 
86 Bola2 1.552018 1.820475 1.465165 1.285875 0.08256 0.119444 
87 Nox3 0.006174 0.006711 0.006229 0.005119 0.648028 0.155095 
88 Slc11a2 0.160049 0.185315 0.243143 0.302872 0.542801 0.240097 
89 Slc11a2 0.044632 0.03938 0.062076 0.046701 0.475314 0.01464 








APPENDIX XIV. Expression profile of 90 iron metabolism genes in kidney 
Kidney 










+/+ vs -/- 
Standard 
+/+ vs -/- 
2ppm 
1 Ncoa4 1.513559 1.28202 0.898102 0.907504 0.1736 0.950794 
2 Ankrd37 0.029142 0.023148 0.069268 0.028592 0.138407 0.199186 
3 Smad7 0.137197 0.137694 0.088067 0.119587 0.977073 0.30222 
4 Neo1 0.153181 0.177308 0.174018 0.137803 0.541968 0.137172 
5 Mfsd7b 0.085726 0.089446 0.074088 0.078541 0.791126 0.818661 
6 Steap3 0.057907 0.05378 0.061935 0.040484 0.741052 0.124405 
7 Alas2 0.069139 0.034089 0.061478 0.06168 0.220845 0.99273 
8 Steap2 0.312609 0.337242 0.223876 0.243704 0.810188 0.643705 
9 Pcbp2 3.94274 3.598512 3.396793 3.236344 0.318805 0.700694 
10 Slc39a8 0.458194 0.379128 0.254521 0.448878 0.49605 0.441777 
11 Slc39a14 0.211629 0.166485 0.167922 0.206643 0.266334 0.199727 
12 Hmox2 0.42318 0.407004 0.337739 0.389714 0.692318 0.538234 
13 Slc11a2 0.34183 0.360294 0.293732 0.335713 0.772855 0.5823 
14 Il12a 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
15 Heph 0.05569 0.063917 0.0531 0.056522 0.627037 0.735438 
16 Fbxl5 0.394003 0.419545 0.350427 0.311443 0.304219 0.208803 
17 Slc38a1 0.015691 0.014064 0.024973 0.014994 0.362215 0.076301 
18 Cp 0.249568 0.213611 0.320409 0.332846 0.375082 0.900885 
19 Nox4 1.665862 1.581599 1.157241 1.110812 0.888563 0.906679 
20 Trfr2 0.00564 0.00537 0.005248 0.006483 0.852613 0.512809 
21 Tlr7 0.010414 0.006997 0.015665 0.011231 0.315114 0.169703 
22 Alas1 1.188382 1.01941 1.463099 1.104043 0.605904 0.571103 
23 Aco1 1.406815 1.298365 0.935525 1.169077 0.441333 0.372107 
24 Bmp6 0.26479 0.263341 0.205326 0.292529 0.944581 0.160257 
25 Epo 0.004645 0.003879 0.012059 0.013186 0.234888 0.893449 
26 Fech 0.825439 0.810884 0.632568 0.688628 0.842433 0.521691 
27 Fxn 0.24796 0.24508 0.172015 0.194118 0.90697 0.476215 
28 Ifnab 0.021862 0.015342 0.006295 0.011546 0.172385 0.085648 
29 Il1b 0.02121 0.020247 0.024906 0.020693 0.838522 0.608971 
30 Lcn2 0.015717 0.022173 0.045399 0.039986 0.620179 0.922122 
31 Smad4 0.554963 0.59721 0.577837 0.611259 0.510358 0.669206 
32 Trim27 0.331102 0.342718 0.29072 0.294957 0.805476 0.916454 
33 Saa1 0.017354 0.010151 0.014972 0.053176 0.73087 0.5414 





35 Epas1 0.718012 0.655311 0.805434 0.813797 0.490888 0.973427 
36 Fth1 111.9013 110.2752 75.69413 88.44987 0.789045 0.46176 
37 Ftl1 23.54187 25.31998 15.93333 18.4622 0.447805 0.385427 
38 Gast 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
39 Ggh 0.303096 0.302896 0.318241 0.229256 0.996568 0.009933 
40 Herc2 0.301479 0.31797 0.301293 0.250579 0.717737 0.116359 
41 Hfe 0.100404 0.106231 0.09523 0.079177 0.751637 0.231272 
42 Hif1a 0.310568 0.319291 0.296756 0.276532 0.894726 0.807805 
43 Hmox1 0.143608 0.133694 0.126591 0.09178 0.814412 0.109713 
44 Id1 0.454278 0.541832 0.616308 0.568121 0.455781 0.83062 
45 Ifna2 0.011409 0.00796 0.005141 0.007574 0.032769 0.287812 
46 Ifna4 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
47 Ifnb1 0.006066 0.004712 0.003964 0.003857 0.240382 0.883257 
48 Il10 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
49 Il1a 0.006141 0.005932 0.006022 0.007235 0.910309 0.692199 
50 Nos2 0.56329 0.594628 0.310762 0.383068 0.800678 0.710929 
51 Spic 0.004645 0.003879 0.004206 0.003548 0.234888 0.32807 
52 Stat3 0.451136 0.439682 0.433415 0.466417 0.849857 0.573612 
53 Tfrc 0.313642 0.388359 0.670269 0.917032 0.13453 0.551542 
54 Pcbp1 1.730188 1.72758 1.494005 1.564463 0.990326 0.691797 
55 Eif2ak1 0.387529 0.413438 0.324574 0.337392 0.462764 0.748108 
56 Slc11a1 0.008045 0.007602 0.011372 0.008899 0.609153 0.176223 
57 Neu3 0.020303 0.023411 0.022828 0.017948 0.098291 0.132742 
58 Slc40a1 0.295049 0.307257 0.264701 0.308182 0.857874 0.603238 
59 Il22 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
60 Hp 0.045247 0.063056 0.179769 0.283182 0.849294 0.689208 
61 Hpx 0.067717 0.021878 0.079114 0.442642 0.445107 0.121291 
62 Pcbp4 0.100075 0.136438 0.091864 0.120656 0.049089 0.399312 
63 Pcbp3 0.178384 0.167869 0.167172 0.165449 0.627297 0.951444 
64 Ireb2 0.549021 0.63373 0.409 0.444599 0.147266 0.70143 
65 Ndfip1 2.242544 2.283968 2.021963 1.98158 0.830606 0.861206 
66 Glrx3 0.897545 0.941499 0.773776 0.739943 0.417121 0.627132 
67 Cisd2 0.140847 0.139944 0.083697 0.110701 0.973374 0.206642 
68 Slc25a37 0.153897 0.120264 0.147322 0.109714 0.079446 0.045882 
69 Slc48a1 1.238284 0.584859 1.067668 0.520679 0.003822 0.012404 
70 Asb11 0.032436 0.015521 0.027778 0.028678 0.218226 0.96164 
71 Hfe2 0.004645 0.004465 0.004843 0.006662 0.868974 0.447046 
72 Steap1 0.043614 0.042866 0.078579 0.025085 0.979786 0.056822 
73 Tmprss6 0.00738 0.007922 0.009734 0.012486 0.742665 0.55675 
74 Cybrd1 0.007195 0.006367 0.006078 0.005117 0.729813 0.711579 





76 Tlr9 0.013582 0.008742 0.013567 0.018153 0.007584 0.427263 
77 Hamp 0.016196 0.009593 0.003802 0.009876 0.664902 0.36705 
78 Steap4 0.010714 0.039598 0.075009 0.023004 0.151848 0.118793 
79 Aco2 7.066896 7.880921 6.705484 7.121036 0.315248 0.773014 
80 Tlr3 0.046437 0.038095 0.039815 0.046217 0.385355 0.493834 
81 Cisd1 2.441503 2.407144 1.469222 2.041546 0.929555 0.24164 
82 Slc25a38 0.006424 0.004918 0.004064 0.00511 0.415238 0.358185 
83 Slc25a28 0.202118 0.177702 0.165656 0.1695 0.408074 0.918535 
84 Nox1 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
85 Fam132b 0.02495 0.027947 0.030023 0.023723 0.634437 0.347538 
86 Bola2 1.353151 1.467038 1.375678 1.227972 0.43727 0.203749 
87 Nox3 0.004645 0.003879 0.003802 0.003548 0.234888 0.658763 
88 Slc11a2 0.22337 0.245074 0.222163 0.288672 0.760397 0.461964 
89 Slc11a2 0.072442 0.086877 0.058186 0.062868 0.445062 0.521276 
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